Whole Body Health Sale

Life Extension Magazine

Online References for Life Extension Magazine

November 2003 - As We See It: Startling New Findings About Homocysteine - Reference 13

Abbasi F, Facchini F, Humphreys MH, Reaven GM. Plasma homocysteine concentrations in healthy volunteers are not related to differences in insulin-mediated glucose disposal. Atherosclerosis. 1999 Sep;146(1):175-8.

Abbate R, Sardi I, Pepe G, Marcucci R, Brunelli T, Prisco D, Fatini C, Capanni M, Simonetti I, Gensini GF. The high prevalence of thermolabile 5-10 methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haemost. 1998 Apr;79(4):727-30.

Abby SL, Harris IM, Harris KM. Homocysteine and cardiovascular disease. J Am Board Fam Pract. 1998 Sep-Oct;11(5):391-8.

Accinni R, Campolo J, Bartesaghi S, De Leo G, Lucarelli C, Cursano CF, Parodi O. High-performance liquid chromatographic determination of total plasma homocysteine with or without internal standards. J Chromatogr A. 1998 Dec 18;828(1-2):397-400.

Adams M, Smith PD, Martin D, Thompson JR, Lodwick D, Samani NJ. Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. QJM. 1996 Jun;89(6):437-44.

Adams AK, Wermuth EO, McBride PE. Antioxidant vitamins and the prevention of coronary heart disease. Am Fam Physician. 1999 Sep 1;60(3):895-904.

Agardh CD, Agardh E, Andersson A, Hultberg B. Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest. 1994 Dec;54(8):637-41.

Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994 Mar;106(1):9-19.

Ali A, Mehra MR, Lavie CJ, Malik FS, Murgo JP, Lohmann TP, Li S, Lin HC, Milani RV. Modulatory impact of cardiac rehabilitation on hyperhomocysteinemia in patients with coronary artery disease and "normal" lipid levels. Am J Cardiol. 1998 Dec 15;82(12):1543-5, A8.

Allain P, Olivier E, Le Bouil A, Benoit C, Geslin P, Tadei A. [Moderate hyper-homocysteinemia and coronary involvement] Presse Med. 1996 Dec 21;25(40):2042. French.

Alpert MA. Homocyst(e)ine, atherosclerosis, and thrombosis. South Med J. 1999 Sep;92(9):858-65.

Ambrosi P, Garcon D, Riberi A, Habib G, Barlatier A, Kreitmann B, Rolland PH, Bouvenot G, Luccioni R, Metras D. Association of mild hyperhomocysteinemia with cardiac graft vascular disease. Atherosclerosis. 1998 Jun;138(2):347-50.

Ambrosi P, Rolland PH, Bodard H, Barlatier A, Charpiot P, Guisgand G, Friggi A, Ghiringhelli O, Habib G, Bouvenot G, Garcon D, Luccioni R. Effects of folate supplementation in hyperhomocysteinemic pigs. J Am Coll Cardiol. 1999 Jul;34(1):274-9.

Ambrosi P, Barlatier A, Artaud-Navarro A, Habib G, Ferracci A, Boussuges A, Garcon D, Bouvenot G, Luccioni R. [Homocysteine and coronary events in coronary disease patients] Ann Cardiol Angeiol (Paris). 1999 Mar;48(3):185-9. French.

Ambrosi P, Rolland P, Garcon D. [Homocysteine, a risk factor of atherosclerosis] Arch Mal Coeur Vaiss. 1996 Dec;89(12):1667-71. French.

Anand SS, Yusuf S, Vuksan V, Devanesen S, Montague P, Kelemen L, Bosch J, Sigouin C, Teo KK, Lonn E, Gerstein HC, Hegele RA, McQueen M. The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. Can J Cardiol. 1998 Nov;14(11):1349-57.

Andersson A, Isaksson A, Brattstrom L, Israelsson B, Hultberg B. Influence of hydrolysis on plasma homocysteine determination in healthy subjects and patients with myocardial infarction. Atherosclerosis. 1991 Jun;88(2-3):143-51.

Anderson JL, King GJ, Thomson MJ, Todd M, Bair TL, Muhlestein JB, Carlquist JF. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol. 1997 Nov 1;30(5):1206-11.

Anker G, Lonning PE, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int J Cancer. 1995 Jan 27;60(3):365-8.

Anon. B vitamins and heart disease. Harv Health Lett. 1998 Oct;23(12):8.

Anon. Assessment of laboratory tests for plasma homocysteine--selected laboratories, July-September 1998. MMWR Morb Mortal Wkly Rep. 1999 Nov 12;48(44):1013-5.

Anon. B vitamins and heart-disease risk. Harv Heart Lett. 1998 Jun;8(10):4-5.

Anon. Betaine for homocystinuria. Med Lett Drugs Ther. 1997 Jan 31;39(993):12.

Anon. B vitamins and the heart: what men can learn from women. Harv Mens Health Watch. 1998 Jun;2(11):4-6.

Anon. [Prevention of arteriosclerosis from the very beginning. Therapy with specific synergistic vitamins against hyperhomocysteinemia] Fortschr Med Suppl. 1993;145:1-19. German.

Ambrosi P, Barlatier A, Habib G, Garcon D, Kreitman B, Roland PH, Saingra S, Metras D, Luccioni R. Hyperhomocysteinaemia in heart transplant recipients. Eur Heart J. 1994 Sep;15(9):1191-5.

Andreotti F, Burzotta F, Mazza A, Manzoli A, Robinson K, Maseri A. Homocysteine and arterial occlusive disease: a concise review. Cardiologia. 1999 Apr;44(4):341-5. Araki A, Ito H. [Perspective of dietary management and exercise therapy in diabetes mellitus] Nippon Rinsho. 1999 Mar;57(3):650-6. Japanese.

Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P, Thysell H. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation. 1996 Feb 15;61(3):509-12.

Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest. 1996 Feb;56(1):41-6.

Arnadottir M, Hultberg B, Wahlberg J, Fellstrom B, Dimeny E. Serum total homocysteine concentration before and after renal transplantation. Kidney Int. 1998 Oct;54(4):1380-4.

Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995 Aug;24(4):704-9.

Aro A, Alfthan G. [Homocysteine as a risk factor for atherosclerosis] Duodecim. 1997;113(16):1509, 1511-2. Finnish.

Aronow WS, Ahn C. Association between plasma homocysteine and coronary artery disease in older persons. Am J Cardiol. 1997 Nov 1;80(9):1216-8.

Ascherio A, Willett WC. New directions in dietary studies of coronary heart disease. J Nutr. 1995 Mar;125(3 Suppl):647S-655S.

Auer J, Eber B. Homocysteine and fibrinolysis in acute occlusive coronary events. Lancet. 1999 Oct 23;354(9188):1474-5.

Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol. 1995 Jul;6(1):121-5.

Bakker RC, Brandjes DP. Hyperhomocysteinaemia and associated disease. Pharm World Sci. 1997 Jun;19(3):126-32.

Bakker RC, Brandjes DP, Snel P, Lawson JA, Lindeman J, Batchelor D. Malabsorption syndrome associated with ulceration of the stomach and small bowel caused by chronic intestinal ischemia in a patient with hyperhomocysteinemia. Mayo Clin Proc. 1997 Jun;72(6):546-50.

Ballal RS, Jacobsen DW, Robinson K. Homocysteine: update on a new risk factor. Cleve Clin J Med. 1997 Nov-Dec;64(10):543-9.

Ballantyne CM. Current thinking in lipid lowering. Am J Med. 1998 Jun 2;104(6A):33S-41S.

Barnabei VM, Phillips TM, Hsia J. Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Womens Health Gend Based Med. 1999 Nov;8(9):1167-72.

Bauer FW. Hyperhomocysteinemia. Am J Clin Pathol. 1997 Jul;108(1):115.

Beaumont V, Malinow MR, Sexton G, Wilson D, Lemort N, Upson B, Beaumont JL. Hyperhomocyst(e)inemia, anti-estrogen antibodies and other risk factors for thrombosis in women on oral contraceptives. Atherosclerosis. 1992 Jun;94(2-3):147-52.

Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, Stoll M, Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999 Jul 9;13(10):F63-70.

Benoit C, Furber A, Le Bouil A, Merheb M, Tadei A, Allain P, Geslin P. [Plasma homocysteine is not a predictive factor of restenosis after coronary angioplasty] Arch Mal Coeur Vaiss. 1999 Nov;92(11):1457-60. French.

Berg K. [Molecular biology in the diagnosis of cardiovascular diseases] Tidsskr Nor Laegeforen. 1998 Jun 10;118(15):2370-4. Norwegian.

Berg K, Malinow MR, Kierulf P, Upson B. Population variation and genetics of plasma homocyst(e)ine level. Clin Genet. 1992 Jun;41(6):315-21.

Berg K. Molecular genetics and genetic epidemiology of cardiovascular diseases and diabetes. Introductory remarks: risk factor levels and variability. Ann Med. 1992 Oct;24(5):343-7.

Bergmark C, Mansoor MA, Swedenborg J, de Faire U, Svardal AM, Ueland PM. Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50--effect of smoking and extent of disease. Eur J Vasc Surg. 1993 Jul;7(4):391-6.

50 Berwanger CS, Jeremy JY, Stansby G. Homocysteine and vascular disease. Br J Surg. 1995 Jun;82(6):726-31.

Breteler MM, Bots ML, Ott A, Hofman A. Risk factors for vascular disease and dementia. Haemostasis. 1998 May-Aug;28(3-4):167-73. Review.

Blacher J, Montalescot G, Ankri A, Chadefaux-Vekemans B, Benzidia R, Grosgogeat Y, Kamoun P, Thomas D. [Hyperhomocysteinemia in coronary artery diseases. Apropos of a study on 102 patients] Arch Mal Coeur Vaiss. 1996 Oct;89(10):1241-6. French.

Blacher J, Ducimetiere P, Safar M. [Homocysteine and cardiovascular disease: what is the connection?] Presse Med. 1999 Oct 16;28(31):1717-22. French.

Blacher J, Demuth K, Guerin AP, Vadez C, Moatti N, Safar ME, London GM. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol. 1999 Jul-Aug;12(4):248-55.

Blann AD. Endothelial cell damage and homocysteine. Atherosclerosis. 1992 May;94(1):89-91.

Blom HJ. Mutated 5,10-methylenetetrahydrofolate reductase and moderate hyperhomocysteinaemia. Eur J Pediatr. 1998 Apr;157 Suppl 2:S131-4.

Bloomgarden ZT. International Diabetes Federation Meeting, 1997, and other recent meetings. Atherosclerosis and related topics. Diabetes Care. 1998 Aug;21(8):1356-63.

Blundell G, Rose FA, Tudball N. Homocysteine induced endothelial cell toxicity and its protection. Biochem Soc Trans. 1994 Aug;22(3):341S.

Bobak M, Hense HW, Kark J, Kuch B, Vojtisek P, Sinnreich R, Gostomzyk J, Bui M, von Eckardstein A, Junker R, Fobker M, Schulte H, Assmann G, Marmot M. An ecological study of determinants of coronary heart disease rates: a comparison of Czech, Bavarian and Israeli men. Int J Epidemiol. 1999 Jun;28(3):437-44.

Boers G. Moderate hyperhomocysteinaemia and vascular disease: evidence, relevance and the effect of treatment. Eur J Pediatr. 1998 Apr;157 Suppl 2:S127-30.

Boers GH. Hyperhomocysteinaemia: a newly recognized risk factor for vascular disease. Neth J Med. 1994 Jul;45(1):34-41.

Boers GH. The case for mild hyperhomocysteinaemia as a risk factor. J Inherit Metab Dis. 1997 Jun;20(2):301-6.

Bollani G, Ferrari R, Bersatti F, Ferrari M, Cattaneo M, Zighetti ML, Visioli O, Assanelli D. [A hyperhomocysteinemia study in a population with a familial factor for acute myocardial infarct and sudden cardiac death at a young age] Cardiologia. 1999 Jan;44(1):75-81. Italian.

Borst MM, Deussen A, Schrader J. S-adenosylhomocysteine hydrolase activity in human myocardium. Cardiovasc Res. 1992 Feb;26(2):143-7.

Bortolotto LA, Safar ME, Billaud E, Lacroix C, Asmar R, London GM, Blacher J. Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension. 1999 Oct;34(4 Pt 2):837-42.

Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis. 1995 Jul;116(1):147-51.

Bostom AG, Shemin D, Yoburn D, Fisher DH, Nadeau MR, Selhub J. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis. 1996 Feb;120(1-2):241-4.

Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. 1996 Jan;49(1):147-52.

Bostom AG, Eaton CB, Yanek L, McQuade W, Catalfamo J, Selhub J. Elevations in total plasma homocysteine in premature coronary artery, cerebrovascular and peripheral vascular disease. Atherosclerosis. 1993 Aug;102(1):121-4.

Bostom AG, Yanek L, Hume AL, Eaton CB, McQuade W, Nadeau M, Perrone G, Jacques PF, Selhub J. High dose ascorbate supplementation fails to affect plasma homocyst(e)ine levels in patients with coronary heart disease. Atherosclerosis. 1994 Dec;111(2):267-70.

Bostom AG, Shemin D, Lapane KL, Sutherland P, Nadeau MR, Wilson PW, Yoburn D, Bausserman L, Tofler G, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis. 1996 Aug 23;125(1):91-101.

Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2554-8.

Bostom AG, Gohh RY, Tsai MY, Hopkins-Garcia BJ, Nadeau MR, Bianchi LA, Jacques PF, Rosenberg IH, Selhub J. Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant recipients. Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):1894-900.

Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, Jacques PF, Wilson PW. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med. 1999 May 24;159(10):1077-80.

Bostom AG, Bausserman L, Jacques PF, Liaugaudas G, Selhub J, Rosenberg IH. Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine. Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2241-4.

Bostom AG, Gohh RY, Liaugaudas G, Beaulieu AJ, Han H, Jacques PF, Dworkin L, Rosenberg IH, Selhub J. Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid. Atherosclerosis. 1999 Jul;145(1):221-4.

Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997 Jul;52(1):10-20.

Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, Wilson PW, Wolf PA. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med. 1999 Sep 7;131(5):352-5.

Bostom AG, Selhub J. Homocysteine and arteriosclerosis: subclinical and clinical disease associations. Circulation. 1999 May 11;99(18):2361-3.

Bots ML, Launer LJ, Lindemans J, Hofman A, Grobbee DE. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study. J Intern Med. 1997 Oct;242(4):339-47.

Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, Koudstaal PJ, Grobbee DE. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med. 1999 Jan 11;159(1):38-44.

Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995 Oct 4;274(13):1049-57.

Bova I, Chapman J, Sylantiev C, Korczyn AD, Bornstein NM. The A677V methylenetetrahydrofolate reductase gene polymorphism and carotid atherosclerosis. Stroke. 1999 Oct;30(10):2180-2.

Braun WE, Protiva DA, Gifford RW Jr, Straffon RA. Hyperhomocysteinemia and other coronary risk factors in 20-year renal transplant recipients (level 5A) with and without coronary heart disease. Transplant Proc. 1999 Feb-Mar;31(1-2):1280-2.

Breteler MM, Bots ML, Ott A, Hofman A. Risk factors for vascular disease and dementia. Haemostasis. 1998 May-Aug;28(3-4):167-73.

Brouwer DA, Leerink CB, Steward HN, Kroon TA, Suverkropp GH, Romer JW, Volmer M, Muskiet FA. Lipids, apolipoprotein-E genotypes and other risk factors of patients with coronary artery disease in Curacao. West Indian Med J. 1997 Jun;46(2):47-52.

Brouwer DA, Welten HT, van Doormaal JJ, Reijngoud DJ, Muskiet FA. [Recommended dietary allowance of folic acid is insufficient for optimal homocysteine levels] Ned Tijdschr Geneeskd. 1998 Apr 4;142(14):782-6. Dutch.

Brown JC, Rosenquist TH, Monaghan DT. ERK2 activation by homocysteine in vascular smooth muscle cells. Biochem Biophys Res Commun. 1998 Oct 29;251(3):669-76.

Brugada R, Marian AJ. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis. 1997 Jan 3;128(1):107-12.

Brulez HF, van Guldener C, Donker AJ, ter Wee PM. The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant. 1999 Jan;14(1):154-9.

Butterworth CE Jr. Folate status, women's health, pregnancy outcome, and cancer. J Am Coll Nutr. 1993 Aug;12(4):438-41.

Bux-Gewehr I, Nacke A, Feurle GE. Recurring myocardial infarction in a 35 year old woman. Heart. 1999 Mar;81(3):316-7.

Cacoub P, Gatel A, Sbai A, Piette JC, Godeau P. [Hyperhomocysteinemia, atherosclerosis and arterial and venous thrombosis] Ann Med Interne (Paris). 1996;147(5):352-60. French.

Cafagna D, Ponte E. [Hyperhomocysteinemia: a new independent vascular risk factor?] Minerva Cardioangiol. 1997 Jan-Feb;45(1-2):49-55. Italian.

Cambou JP. [Are there environmental protective factors?] Arch Mal Coeur Vaiss. 1998 Oct;91 Spec No 5:27-31.

Cambou JP. [Epidemiology of atherosclerosis: risks and paradoxes] Rev Prat. 1999 Dec 1;49(19):2094-9. French.

Carlsen SM, Folling I, Grill V, Bjerve KS, Schneede J, Refsum H. Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease. Scand J Clin Lab Invest. 1997 Oct;57(6):521-7.

Carluccio M, Vanuzzo D, Pilotto L, Fioretti P, Quadrifoglio F, Diviacco S, Mariani M, De Caterina R. [The genetic component of coronary risk. II] Cardiologia. 1999 Feb;44(2):155-67. Italian.

Carmody BJ, Arora S, Avena R, Cosby K, Sidawy AN. Folic acid inhibits homocysteine-induced proliferation of human arterial smooth muscle cells. J Vasc Surg. 1999 Dec;30(6):1121-8.

Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis. 1996 Jul;124 Suppl:S1-9.

100. Cattaneo M, Baglietto L, Zighetti ML, Bettega D, Robertson C, Costa A, Mannucci PM, Decensi A. Tamoxifen reduces plasma homocysteine levels in healthy women. Br J Cancer. 1998 Jun;77(12):2264-6.

Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost. 1999 Feb;81(2):165-76.

Cattaneo M. Hyperhomocysteinemia: a risk factor for arterial and venous thrombotic disease. Int J Clin Lab Res. 1997;27(3):139-44.

Causse E, Siri N, Bellet H, Champagne S, Bayle C, Valdiguie P, Salvayre R, Couderc F. Plasma homocysteine determined by capillary electrophoresis with laser-induced fluorescence detection. Clin Chem. 1999 Mar;45(3):412-4.

Cerone R, Minniti G, Piana A, Armani U, Susco G, Bertolini S. Screening for hyperhomocysteinemia in young adults with premature coronary artery disease. Southeast Asian J Trop Med Public Health. 1999;30 Suppl 2:148.

Chacko KA. Plasma homocysteine levels in patients with coronary heart disease. Indian Heart J. 1998 May-Jun;50(3):295-9.

Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 1999 Mar 9;99(9):1156-60.

Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet. 1998 Jan 3;351(9095):36-7.

Chambers JC, Obeid OA, Kooner JS. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):2922-7.

Chao CL, Tsai HH, Lee CM, Hsu SM, Kao JT, Chien KL, Sung FC, Lee YT. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis. 1999 Dec;147(2):379-86.

Charpiot P, Bescond A, Augier T, Chareyre C, Fraterno M, Rolland PH, Garcon D. Hyperhomocysteinemia induces elastolysis in minipig arteries: structural consequences, arterial site specificity and effect of captopril-hydrochlorothiazide. Matrix Biol. 1998 Dec;17(8-9):559-74.

Chasan-Taber L, Selhub J, Rosenberg IH, Malinow MR, Terry P, Tishler PV, Willett W, Hennekens CH, Stampfer MJ. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr. 1996 Apr;15(2):136-43.

Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, Jungers P. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl. 1993 Jun;41:S72-7.

Chauveau P, Chadefaux B, Coude M, Aupetit J, Kamoun P, Jungers P. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab. 1996;22(1-3):106-9.

Cheng TO. Another cause of hyperhomocysteinemia. Hosp Pract (Off Ed). 1997 Aug 15;32(8):44.

Cheng TO. Homocysteinaemia and coronary atherosclerosis. Heart. 1997 Apr;77(4):390-1.

Cheng SW, Ting AC, Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg. 1997 May;11(3):217-23.

Cheng TO. Another cause of hyperhomocysteinemia. Hosp Pract (Off Ed). 1997 Aug 15;32(8):44.

Cheng TO. Homocysteine, B vitamins, and atherosclerosis. Circulation. 1999 Jan 26;99(3):459-60

Cheng TO. Hyperhomocysteinemia is a risk factor for coronary artery disease even in the presence of elevated high-density lipoprotein cholesterol. Am J Cardiol. 1997 Sep 1;80(5):683.

Cheng TO. Hyperhomocysteinaemia and the heart. QJM. 1996 Nov;89(11):877-8.

Cheng TO. Hyperhomocysteinaemia. Postgrad Med J. 1997 Sep;73(863):606-7.

Cheng TO. Homocysteinaemia and coronary atherosclerosis. Heart. 1997 Apr;77(4):390-1.

Chilvers MM, Wordsworth P, Stubbs A, Gao XM. TCR usage by homocysteine-specific human CTL. J Immunol. 1998 Apr 15;160(8):3737-42.

Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, Genest J Jr, Rozen R. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol. 1997 Mar;17(3):569-73.

Ciesielski-Carlucci C, Lee BK, Boxer LM, Leung LL. A woman who had a stroke, then a myocardial infarction. Lancet. 1997 Apr 26;349(9060):1218.

Clarke R, Fitzgerald D, O'Brien C, O'Farrell C, Roche G, Parker RA, Graham I. Hyperhomocysteinaemia: a risk factor for extracranial carotid artery atherosclerosis. Ir J Med Sci. 1992 Mar;161(3):61-5.

Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991 Apr 25;324(17):1149-55.

Clinton SK, Libby P. Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med. 1992 Dec;116(12):1292-300.

Cohen A. [Atheroma of the aortic arch and embolic risk] Ann Cardiol Angeiol (Paris). 1998 Nov;47(9):683-9. Review. French.

Constans J, Blann AD, Resplandy F, Parrot F, Renard M, Seigneur M, Guerin V, Boisseau M, Conri C. Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction. Br J Haematol. 1999 Dec;107(4):776-8.

Constans J, Blann AD, Resplandy F, Parrot F, Seigneur M, Renard M, Amiral J, Guerin V, Boisseau MR, Conri C. Endothelial dysfunction during acute methionine load in hyperhomocysteinaemic patients. Atherosclerosis. 1999 Dec;147(2):411-3.

Cook RC, Tupper JK, Parker S, Kingsbury K, Frohlich JJ, Abel JG, Gao M, Ellsworth DL, Sholinsky P, Jaquish C, Fabsitz RR, Manolio TA. Coronary heart disease. At the interface of molecular genetics and preventive medicine. Am J Prev Med. 1999 Feb;16(2):122-33. Review.

Cordoba Porras A, Blanco Vaca F, Gonzalez Sastre F. [Hyperhomocysteinemia: a new marker of vascular risk: affected vascular areas, its role in the pathogenesis of arteriosclerosis and thrombosis and treatment] Med Clin (Barc). 1997 Nov 22;109(18):715-25. Spanish.

Cordoba-Porras A, Sanchez-Quesada JL, Gonzalez-Sastre F, Ordonez-Llanos J, Blanco-Vaca F. Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. J Mol Med. 1996 Dec;74(12):771-6.

Cowley G. The heart attackers. Newsweek. 1997 Aug 11;130(6):54-60.

Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med. 1997;2(3):221-6.

Cullen P, von Eckardstein A, Assmann G. Diagnosis and management of new cardiovascular risk factors. Eur Heart J. 1998 Nov;19 Suppl O:O13-9.

Culleton BF, Wilson PW. Cardiovascular disease: risk factors, secular trends, and therapeutic guidelines. J Am Soc Nephrol. 1998 Dec;9(12 Suppl):S5-15.

Czeizel E, Matos L. [The role of hyper-homocysteinemia in the etiology of some vascular diseases] Orv Hetil. 1998 Sep 13;139(37):2191-6. Hungarian.

Dahlen GH, Srinivasan SR, Stenlund H, Wattigney WA, Wall S, Berenson GS. The importance of serum lipoprotein (a) as an independent risk factor for premature coronary artery disease in middle-aged black and white women from the United States. J Intern Med. 1998 Nov;244(5):417-24.

Daly L, Robinson K, Tan KS, Graham IM. Hyperhomocysteinaemia: a metabolic risk factor for coronary heart disease determined by both genetic and environmental influences? Q J Med. 1993 Oct;86(10):685-9.

Dalery K, Lussier-Cacan S, Selhub J, Davignon J, Latour Y, Genest J Jr. Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate. Am J Cardiol. 1995 Jun 1;75(16):1107-11.

Dalton ML, Gadson PF Jr, Wrenn RW, Rosenquist TH. Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J. 1997 Jul;11(8):703-11.

Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk. 1998 Aug;5(4):229-32.

D'Angelo A, Mazzola G, Crippa L, Fermo I, Vigano D'Angelo S. Hyperhomocysteinemia and venous thromboembolic disease. Haematologica. 1997 Mar-Apr;82(2):211-9.

De Groote MA, Testerman T, Xu Y, Stauffer G, Fang FC. Homocysteine antagonism of nitric oxide-related cytostasis in Salmonella typhimurium. Science. 1996 Apr 19;272(5260):414-7.

de Jong SC, Stehouwer CD, van den Berg M, Vischer UM, Rauwerda JA, Emeis JJ. Endothelial marker proteins in hyperhomocysteinemia. Thromb Haemost. 1997 Nov;78(5):1332-7.

de Jong SC, Stehouwer CD, van den Berg M, Kostense PJ, Alders D, Jakobs C, Pals G, Rauwerda JA. Determinants of fasting and post-methionine homocysteine levels in families predisposed to hyperhomocysteinemia and premature vascular disease. Arterioscler Thromb Vasc Biol. 1999 May;19(5):1316-24.

de Lorgeril M, Salen P, Paillard F, Lacan P, Richard G. Lipid-lowering drugs and homocysteine. Lancet. 1999 Jan 16;353(9148):209-10.

Deloughery TG, Evans A, Sadeghi A, McWilliams J, Henner WD, Taylor LM Jr, Press RD. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Circulation. 1996 Dec 15;94(12):3074-8.

Demuth K, Atger V, Borderie D, Benoit MO, Sauvaget D, Lotersztajn S, Moatti N. Homocysteine decreases endothelin-1 production by cultured human endothelial cells. Eur J Biochem. 1999 Jul;263(2):367-76.

den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998 Dec;80(6):874-7.

den Heijer M, Brouwer IA, Bos GM, Blom HJ, van der Put NM, Spaans AP, Rosendaal FR, Thomas CM, Haak HL, Wijermans PW, Gerrits WB. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol. 1998 Mar;18(3):356-61.

de Jong SC, van den Berg M, Rauwerda JA, Stehouwer CD. Hyperhomocysteinemia and atherothrombotic disease. Semin Thromb Hemost. 1998;24(4):381-5.

Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int Suppl. 1996 Dec;57:S11-7.

DeRose DJ, Mullen K, Muscat J. Expanding and understanding risk factors for coronary heart disease. JAMA. 1997 Aug 27;278(8):636.

De Stefano V, Dekou V, Nicaud V, Chasse JF, London J, Stansbie D, Humphries SE, Gudnason V. Linkage disequilibrium at the cystathionine beta synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine. The Ears II Group. European Atherosclerosis Research Study. Ann Hum Genet. 1998 Nov;62 ( Pt 6):481-90.

Deussen A, Henrich M, Hamacher K, Borst MM, Herzog H, Coenen HH, Stocklin G, Feinendegen LE, Schrader J. Noninvasive assessment of regional cardiac adenosine using positron emission tomography. J Nucl Med. 1992 Dec;33(12):2138-44.

de Valk HW, van Eeden MK, Banga JD, van der Griend R, de Groot E, Haas FJ, Meuwissen OJ, Duran M, Smeitink JA, Poll-The BT, de Klerk JB, Wittebol-Post D, Rolland MO. Evaluation of the presence of premature atherosclerosis in adults with heterozygosity for cystathionine-beta-synthase deficiency. Stroke. 1996 Jun;27(6):1134-6.

De Vriese AS, De Sutter JH, De Buyzere M, Duprez D. Mild to moderate hyperhomocysteinaemia in cardiovascular disease. Acta Cardiol. 1998;53(6):337-44.

Dierkes J, Kroesen M, Pietrzik K. Folic acid and Vitamin B6 supplementation and plasma homocysteine concentrations in healthy young women. Int J Vitam Nutr Res. 1998;68(2):98-103.

Dierkes J, Bisse E, Nauck M, Orth M, Mayer H, Luley C, Wieland H. The diagnostic value of serum homocysteine concentration as a risk factor for coronary artery disease. Clin Chem Lab Med. 1998 Jun;36(7):453-7.

Dimeny E, Hultberg B, Wahlberg J, Fellstrom B, Arnadottir M. Serum total homocysteine concentration does not predict outcome in renal transplant recipients. Clin Transplant. 1998 Dec;12(6):563-8.

Domagala TB, Libura M, Gozdecka H, Krzanowski M, Szczeklik A. [Familial hyperhomocysteinemia with early development of atherosclerosis] Pol Arch Med Wewn. 1996 Oct;96(4):354-8. Polish.

Domagala B, Sanak M, Czachor R, Szczeklik A. [Hyperhomocysteinemia and its relationship to atherosclerosis] Pol Arch Med Wewn. 1997 Aug;98(8):153-62. Polish.

Domagala TB, Undas A, Libura M, Szczeklik A. Pathogenesis of vascular disease in hyperhomocysteinaemia. J Cardiovasc Risk. 1998 Aug;5(4):239-47.

Donner MG, Klein GK, Mathes PB, Schwandt P, Richter WO. Plasma total homocysteine levels in patients with early-onset coronary heart disease and a low cardiovascular risk profile. Metabolism. 1998 Mar;47(3):273-9.

Donner MG, Schwandt P, Richter WO. [Homocysteine and coronary heart disease. Is slight or moderate homocysteinemia related to increased risk of coronary heart disease?] Fortschr Med. 1997 Jul 20;115(20-21):24-30. German.

Drown DJ. Homocysteine: an independent risk factor associated with coronary disease and other arterial occlusive diseases in adults. Prog Cardiovasc Nurs. 1995 Fall;10(4):37-8.

Drozdzik M. [Clinical significance of modulating homocysteine metabolism] Pol Tyg Lek. 1992 Oct 19-26;47(42-43):972-4. Review. Polish.

Ducloux D, Fournier V, Rebibou JM, Bresson-Vautrin C, Gibey R, Chalopin JM. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine. Clin Nephrol. 1998 Apr;49(4):232-5.

Ducloux D, Chalopin JM. Homocysteine in cerebral macroangiopathy and microangiopathy. Lancet. 1999 Sep 18;354(9183):1029-30.

Dudman NP, Hicks C, Wang J, Wilcken DE. Human arterial endothelial cell detachment in vitro: its promotion by homocysteine and cysteine. Atherosclerosis. 1991 Nov;91(1-2):77-83.

Dudman NP. An alternative view of homocysteine. Lancet. 1999 Dec 1;354(9195):2072-4.

Dudman NP, Wilcken DE, Stocker R. Circulating lipid hydroperoxide levels in human hyperhomocysteinemia. Relevance to development of arteriosclerosis. Arterioscler Thromb. 1993 Apr;13(4):512-6.

Dudman NP, Hicks C, Lynch JF, Wilcken DE, Wang J. Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro. Arterioscler Thromb. 1991 May-Jun;11(3):663-70.

Dudman NP, Lynch J, Wang J, Wilcken DE. Failure to detect homocysteine in the acid-hydrolysed plasmas of recent myocardial infarct patients. Atherosclerosis. 1991 Feb;86(2-3):201-9.

Dudman NP, Wilcken DE, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb. 1993 Sep;13(9):1253-60.

Duell PB, Malinow MR. Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol. 1997 Feb;8(1):28-34.

Dunn J, Title LM, Bata I, Johnstone DE, Kirkland SA, O'Neill BJ, Zayed E, MacDonald MC, Dempsey G, Nassar B. Relation of a common mutation in methylenetetrahydrofolate reductase to plasma homocysteine and early onset coronary artery disease. Clin Biochem. 1998 Mar;31(2):95-100.

Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J. 1997 Nov;11(13):1157-68.

Eaton CB, Bostom AG, Yanek L, Laurino JP, McQuade W, Hume A, Selhub J. Family history and premature coronary heart disease. J Am Board Fam Pract. 1996 Sep-Oct;9(5):312-8.

Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol. 1996 Apr 1;77(9):759-61.

Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999 Sep 7;131(5):363-75.

Elias PR, Hann AC, Curtis CG, Rose FA, Tudball N. A rat vein perfusion model for studying homocysteine induced toxicity. Biochem Soc Trans. 1994 Aug;22(3):342S.

Ellis JM, McCully KS. Prevention of myocardial infarction by vitamin B6. Res Commun Mol Pathol Pharmacol. 1995 Aug;89(2):208-20.

Ellison RC, Zhang Y, Myers RH, Swanson JL, Higgins M, Eckfeldt J. Lewis blood group phenotype as an independent risk factor for coronary heart disease (the NHLBI Family Heart Study). Am J Cardiol. 1999 Feb 1;83(3):345-8.

Emsley AM, Jeremy JY, Gomes GN, Angelini GD, Plane F. Investigation of the inhibitory effects of homocysteine and copper on nitric oxide-mediated relaxation of rat isolated aorta. Br J Pharmacol. 1999 Feb;126(4):1034-40.

Engman M. Homocysteinemia: new information about an old risk factor for vascular disease. J Insur Med. 1998;30(4):231-6.

Eritsland J, Arnesen H, Seljeflot I, Abdelnoor M, Gronseth K, Berg K, Malinow MR. Influence of serum lipoprotein(a) and homocyst(e)ine levels on graft patency after coronary artery bypass grafting. Am J Cardiol. 1994 Dec 1;74(11):1099-102.

Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO, Kropf J, Kerber S, Breithardt G, Assmann G, Cullen P. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2355-63.

Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):1947-53.

Evers S, Koch HG, Grotemeyer KH, Lange B, Deufel T, Ringelstein EB. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol. 1997 Oct;54(10):1276-82.

Falcon CR. [Moderate hyperhomocysteinemia and atherothrombosis] Medicina (B Aires). 1998;58(5 Pt 1):511-4. Spanish.

Falcon CR, Carreras LO. [Moderate hyperhomocysteinemia: physiopathology of the endothelial lesion and its clinical implications] Sangre (Barc). 1998 Feb;43(1):47-54. Review. Spanish.

Fanapour PC, Yug B, Kochar MS. Hyperhomocysteinemia: an additional cardiovascular risk factor. WMJ. 1999 Dec;98(8):51-4. Review.

Fallest-Strobl PC, Koch DD, Stein JH, McBride PE. Homocysteine: a new risk factor for atherosclerosis. Am Fam Physician. 1997 Oct 15;56(6):1607-12, 1615-6.

Farhadi D. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997 Nov 27;337(22):1632; author reply 1632-3.

Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M. Homocysteine in cerebral macroangiography and microangiopathy. Lancet. 1999 May 8;353(9164):1586-7.

Ferguson E, Hogg N, Antholine WE, Joseph J, Singh RJ, Parthasarathy S, Kalyanaraman B. Characterization of the adduct formed from the reaction between homocysteine thiolactone and low-density lipoprotein: antioxidant implications. Free Radic Biol Med. 1999 Apr;26(7-8):968-77.

200. Fijnheer R, Roest M, Haas FJ, De Groot PG, Derksen RH. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. J Rheumatol. 1998 Sep;25(9):1737-42.

Fletcher O, Kessling AM. MTHFR association with arteriosclerotic vascular disease? Hum Genet. 1998 Jul;103(1):11-21

Flynn MA, Herbert V, Nolph GB, Krause G. Atherogenesis and the homocysteine-folate-cobalamin triad: do we need standardized analyses? J Am Coll Nutr. 1997 Jun;16(3):258-67.

Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis CE. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1998 Jul 21;98(3):204-10.

Folsom AR. "New" risk factors for atherosclerotic diseases. Exp Gerontol. 1999 Jul;34(4):483-90.

Fonseca VA, Stone A, Munshi M, Baliga BS, Aljada A, Thusu K, Fink L, Dandona P. Oxidative stress in diabetic macrovascular disease: does homocysteine play a role? South Med J. 1997 Sep;90(9):903-6.

Fonseca VA, Mudaliar S, Schmidt B, Fink LM, Kern PA, Henry RR. Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism. 1998 Jun;47(6):686-9.

Fortin LJ, Genest J Jr. Measurement of homocyst(e)ine in the prediction of arteriosclerosis. Clin Biochem. 1995 Apr;28(2):155-62.

Franken DG, Barentsz JO, Heijstraten FM, Boers GH, Ruijs JH. Imaging of vascular pathology in hyperhomocysteinemic patients with digital subtraction angiography and magnetic resonance techniques. Eur Radiol. 1997;7(8):1335-40.

Freyburger G, Labrouche S, Sassoust G, Rouanet F, Javorschi S, Parrot F. Mild hyperhomocysteinemia and hemostatic factors in patients with arterial vascular diseases. Thromb Haemost. 1997 Mar;77(3):466-71.

Frohlich JJ. Lipoproteins and homocyst(e)ine as risk factors for atherosclerosis: assessment and treatment. Can J Cardiol. 1995 May;11 Suppl C:18C-23C.

Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 May;10(1):111-3.

Futterman LG, Lemberg L. Fifty percent of patients with coronary artery disease do not have any of the conventional risk factors. Am J Crit Care. 1998 May;7(3):240-4.

Futterman LG, Lemberg L. Homocysteine and coronary artery disease. Am J Crit Care. 1997 Jan;6(1):72-7.

Gabor D, Hrnciar J, Hricova I, Zacharova M. [Homocysteine--a routine biochemical parameter in cardiovascular diseases?] Vnitr Lek. 1999 Jan;45(1):40-5. Slovak.

Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, Evans A, Graham IM, Whitehead AS. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation. 1996 Nov 1;94(9):2154-8.

Gao W, Jiang N, Meng Z, Tang J. Hyperhomocysteinemia and hyperlipidemia in coronary heart disease. Chin Med J (Engl). 1999 Jul;112(7):586-9.

Gao W, Jiang N, Zhu G. [The mechanisms of hyperhomocysteinemia in coronary heart disease] Zhonghua Yi Xue Za Zhi. 1998 Nov;78(11):821-3. Chinese.

Gao XM, Wordsworth P, McMichael AJ, Kyaw MM, Seifert M, Rees D, Dougan G. Homocysteine modification of HLA antigens and its immunological consequences. Eur J Immunol. 1996 Jul;26(7):1443-50.

Gardemann A, Weidemann H, Philipp M, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease. Eur Heart J. 1999 Apr;20(8):584-92.

Genest JJ Jr, McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990 Nov;16(5):1114-9.

Gensini GF, Micheli S, Prisco D, Abbate R. Menopause and risk of cardiovascular disease. Thromb Res. 1996 Oct 1;84(1):1-19.

Gerhard GT, Duell PB. Homocysteine and atherosclerosis. Curr Opin Lipidol. 1999 Oct;10(5):417-28.

Gerhard GT, Sexton G, Malinow MR, Wander RC, Connor SL, Pappu AS, Connor WE. Premenopausal black women have more risk factors for coronary heart disease than white women. Am. J Cardiol. 1998 Nov 1;82(9):1040-5.

Giles WH, Kittner SJ, Anda RF, Croft JB, Casper ML. Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study. Stroke. 1995 Jul;26(7):1166-70.

Gensini GF, Micheli S, Prisco D, Abbate R. Menopause and risk of cardiovascular disease. Thromb Res. 1996 Oct 1;84(1):1-19.

Gheye S, Lakshmi AV, Krishna TP, Krishnaswamy K. Fibrinogen and homocysteine levels in coronary artery disease. Indian Heart J. 1999 Sep-Oct;51(5):499-502.

Gibelin P, Candito M, Houenassi M, Van Obberghen E, Morand P, Baudouy M. [Blood levels of homocysteine in patients under 55 years of age with acute coronary insufficiency] Presse Med. 1997 Oct 11;26(30):1425-8. French.

Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, Faccini G, Pignatti PF, Mazzucco A, Corrocher R. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood. 1998 Jun 1;91(11):4158-63.

Glueck CJ, Shaw P, Lang JE, Tracy T, Sieve-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol. 1995 Jan 15;75(2):132-6.

Glueck CJ, Fontaine RN, Gupta A, Alasmi M. Myocardial infarction in a 35-year-old man with homocysteinemia, high plasminogen activator inhibitor activity, and resistance to activated protein C. Metabolism. 1997 Dec;46(12):1470-2.

Glueck CJ, Lang JE, Tracy T, Sieve-Smith L, Wang P. Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease status in 293 hyperlipidemic patients. Metabolism. 1999 Nov;48(11):1437-44.

Gomes Trolin C, Regland B, Oreland L. Decreased methionine adenosyltransferase activity in erythrocytes of patients with dementia disorders. Eur Neuropsychopharmacol. 1995 Jun;5(2):107-14.

Goracy I, Goracy J, Suliga M, Ciechanowicz A. [C677T gene polymorphism of methylenetetrahydrofolate reductase (MTHFR) in patients with myocardial infarction] Pol Arch Med Wewn. 1999 Oct;102(4):849-54. Polish.

Graham I, Meleady R. Heart attacks and homocysteine. BMJ. 1996 Dec 7;313(7070):1419-20.

Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997 Jun 11;277(22):1775-81.

Grant WB. Milk and other dietary influences on coronary heart disease. Altern Med Rev. 1998 Aug;3(4):281-94.

Green DJ, O'Driscoll JG, Maiorana A, Scrimgeour NB, Weerasooriya R, Taylor RR. Effects of chelation with EDTA and vitamin B therapy on nitric oxide-related endothelial vasodilator function. Clin Exp Pharmacol Physiol. 1999 Nov;26(11):853-6.

Greenlund KJ, Srinivasan SR, Xu JH, Dalferes E Jr, Myers L, Pickoff A, Berenson GS. Plasma homocysteine distribution and its association with parental history of coronary artery disease in black and white children: the Bogalusa Heart Study. Circulation. 1999 Apr 27;99(16):2144-9.

Grundt H, Nilsen DW, Hetland O, Mansoor MA, Aarsland T, Woie L. Atherothrombogenic risk modulation by n-3 fatty acids was not associated with changes in homocysteine in subjects with combined hyperlipidaemia. Thromb Haemost. 1999 Apr;81(4):561-5.

Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. EARS group. Atherosclerosis. 1998 Feb;136(2):347-54.

Gunby P. Lipoprotein patterns, plaque, homocysteine, and hormones among ongoing cardiology studies. JAMA. 1996 Oct 9;276(14):1122-7.

Gupta A, Moustapha A, Jacobsen DW, Goormastic M, Tuzcu EM, Hobbs R, Young J, James K, McCarthy P, van Lente F, Green R, Robinson K. High homocysteine, low folate, and low vitamin B6 concentrations: prevalent risk factors for vascular disease in heart transplant recipients. Transplantation. 1998 Feb 27;65(4):544-50.

Gupta A, Robinson K. Hyperhomocysteinaemia and end stage renal disease. J Nephrol. 1997 Mar-Apr;10(2):77-84

Haagsma CJ, Blom HJ, van Riel PL, van't Hof MA, Giesendorf BA, van Oppenraaij-Emmerzaal D, van de Putte LB. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis. 1999 Feb;58(2):79-84.

Hajjar KA, Jacovina AT. Modulation of annexin II by homocysteine: implications for atherothrombosis. J Investig Med. 1998 Oct;46(8):364-9.

Halvorsen B, Brude I, Drevon CA, Nysom J, Ose L, Christiansen EN, Nenseter MS. Effect of homocysteine on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein. J Lipid Res. 1996 Jul;37(7):1591-600.

Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999 Jul 31;354(9176):407-13.

Hanratty CG, McAuley DF, McGurk C, Young IS, Johnston GD. Homocysteine and endothelial vascular function. Lancet. 1998 Apr 25;351(9111):1288-9.

Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10193-7.

Harpel PC, Borth W. Identification of mechanisms that may modulate the role of lipoprotein(a) in thrombosis and atherogenesis. Ann Epidemiol. 1992 Jul;2(4):413-7.

Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J Nutr. 1996 Apr;126(4 Suppl):1285S-9S.

Havranek EP. Primary prevention of CHD: nine ways to reduce risk. Am Fam Physician. 1999 Mar 15;59(6):1455-63, 1466.

Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood. 1992 Jun 1;79(11):2930-6.

Heinecke JW. Biochemical evidence for a link between elevated levels of homocysteine and lipid peroxidation in vivo. Curr Atheroscler Rep. 1999 Sep;1(2):87-9.

Heistad DD, Lentz SR, Rios CD. Atherosclerotic vascular disease: will folate or gene therapy be useful? Trans Am Clin Climatol Assoc. 1996;108:69-76; discussion 76-7.

Henning BF, Riezler R, Tepel M, Langer K, Raidt H, Graefe U, Zidek W. Evidence of altered homocysteine metabolism in chronic renal failure. Nephron. 1999;83(4):314-22.

Hernanz A, Plaza A, Martin-Mola E, De Miguel E. Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clin Biochem. 1999 Feb;32(1):65-70.

Herrmann W, Quast S, Ullrich M, Schultze H, Bodis M, Geisel J. yperhomocysteinemia in high-aged subjects: relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutation. Atherosclerosis. 1999 May;144(1):91-101.

Herzlich BC, Lichstein E, Schulhoff N, Weinstock M, Pagala M, Ravindran K, Namba T, Nieto FJ, Stabler SP, Allen RH, Malinow MR. Relationship among homocyst(e)ine, vitamin B-12 and cardiac disease in the elderly: association between vitamin B-12 deficiency and decreased left ventricular ejection fraction. J Nutr. 1996 Apr;126(4 Suppl):1249S-53S.

Hiatt WR. Current and future drug therapies for claudication. Vasc Med. 1997;2(3):257-62.

Hirano K, Ogihara T, Miki M, Yasuda H, Tamai H, Kawamura N, Mino M. Homocysteine induces iron-catalyzed lipid peroxidation of low-density lipoprotein that is prevented by alpha-tocopherol. Free Radic Res. 1994 Oct;21(5):267-76.

Hirose S, Kim S, Matsuda A, Itakura Y, Matsumura O, Tamura H, Nagasawa R, Mitarai T, Isoda K. [Effects of folic acid supplementation on hyperhomocysteinemia in CAPD patients: effects on unsaturated fatty acids] Nippon Jinzo Gakkai Shi. 1998 Jan;40(1):8-16. Japanese.

Hladovec J. Homocysteine theory of atherosclerosis. Sb Lek. 1995;96(3):225-30.

Holdt B, Korten G, Knippel M, Lehmann JK, Claus R, Holtz M, Hausmann S. Increased serum level of total homocysteine in CAPD patients despite fish oil therapy. Perit Dial Int. 1996;16 Suppl 1:S246-9.

Hoogeveen EK, Stehouwer CD. Should metformin be used to improve blood lipid pattern in nondiabetic patients with coronary heart disease? J Intern Med. 1996 Jul;240(1):46-7.

Hoogeveen EK, Kostense PJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CD. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus? J Intern Med. 1997 Nov;242(5):389-94.

Hopkins PN, Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1995 Sep;15(9):1314-20.

Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2783-92.

Hornberger J. A cost-benefit analysis of a cardiovascular disease prevention trial, using folate supplementation as an example. Am J Public Health. 1998 Jan;88(1):61-7.

Hornstra G, Barth CA, Galli C, Mensink RP, Mutanen M, Riemersma RA, Roberfroid M, Salminen K, Vansant G, Verschuren PM. Functional food science and the cardiovascular system. Br J Nutr. 1998 Aug;80 Suppl 1:S113-46.

House JD, Brosnan ME, Brosnan JT. Characterization of homocysteine metabolism in the rat kidney. Biochem J. 1997 Nov 15;328 ( Pt 1):287-92.

Hultberg B, Andersson A, Isaksson A. Metabolism of homocysteine, its relation to the other cellular thiols and its mechanism of cell damage in a cell culture line (human histiocytic cell line U-937). Biochim Biophys Acta. 1995 Oct 19;1269(1):6-12.

Hultberg B, Andersson A, Isaksson A. The effects of homocysteine and copper ions on the concentration and redox status of thiols in cell line cultures. Clin Chim Acta. 1997 Jun 27;262(1-2):39-51.

Hultberg B, Andersson A, Isaksson A. Protein binding of homocysteine and other thiols in HeLa cell cultures after addition of homocysteine and copper ions. Clin Chim Acta. 998 Jan 30;269(2):175-84.

Hultberg B, Andersson A, Isaksson A. The cell-damaging effects of low amounts of homocysteine and copper ions in human cell line cultures are caused by oxidative stress. Toxicology. 1997 Nov 21;123(1-2):33-40.

Hussein WI, Green R, Jacobsen DW, Faiman C. Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Ann Intern Med. 1999 Sep 7;131(5):348-51.

Huysmans K, Lins RL, Daelemans R, Zachee P, De Broe ME. Hypertension and accelerated atherosclerosis in endstage renal disease. J Nephrol. 1998 Jul-Aug;11(4):185-95.

Hyanek H, Stribrny J, Sebesta P, Niederle P, Kramar J, Kozich V, Orendac O, Zaykova K, Mandysova E, Boruvka V, Dvorakova J, Taborsky L, Loucka M, Dubska L, Martinikova V, Machackova L, Cabrnochova I. [Hyperhomocysteinemia. A risk factor for the development of vascular diseases not associated with lipid levels] Cas Lek Cesk. 1997 Dec 3;136(23):720-3. Czech.

Ignaszewski AP. Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation. J Heart Lung Transplant. 1999 May;18(5):420-4.

Israelsson B, Brattstrom L, Refsum H. Homocysteine in frozen plasma samples. A short cut to establish hyperhomocysteinaemia as a risk factor for arteriosclerosis? Scand J Clin Lab Invest. 1993 Aug;53(5):465-9.

Istok R, Kovalancik M, Rovensky J. Total plasma homocysteine in patients with gout. J Rheumatol. 1999 Sep;26(9):2068-9.

Iwama Y, Mokuno H, Yokoi H, Daida H, Yamaguchi H, Hosoda Y. [Elevated levels of plasma homocysteine related to saphenous vein graft disease after coronary artery bypass graft surgery] J Cardiol. 1998 Dec;32(6):357-62. Japanese.

Jacob RA, Burri BJ. Oxidative damage and defense. Am J Clin Nutr. 1996 Jun;63(6):985S-990S.

Jacob N, Bruckert E, Giral P, Foglietti MJ, Turpin G. Cysteine is a cardiovascular risk factor in hyperlipidemic patients. Atherosclerosis. 1999 Sep;146(1):53-9.

Janssen MJ, van den Berg M, Stehouwer CD, Boers GH. Hyperhomocysteinaemia: a role in the accelerated atherogenesis of chronic renal failure? Neth J Med. 1995 May;46(5):244-51

Jensen OK, Ingerslev J. [Increased p-homocysteine--a risk factor for thrombosis] Ugeskr Laeger. 1998 Jul 20;160(30):4405-10. Danish.

Joubran R, Asmi M, Busjahn A, Vergopoulos A, Luft FC, Jouma M. Homocysteine levels and coronary heart disease in Syria. J Cardiovasc Risk. 1998 Aug;5(4):257-61.

Jungers P, Massy ZA, Khoa TN, Fumeron C, Labrunie M, Lacour B, Descamps-Latscha B, Man NK. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant. 1997 Dec;12(12):2597-602.

Jungers P, Joly D, Massy Z, Chauveau P, Nguyen AT, Aupetit J, Chadefaux B. Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients. Nephrol Dial Transplant. 1999 Dec;14(12):2903-6.

Jungers P, Chauveau P, Bandin O, Chadefaux B, Aupetit J, Labrunie M, Descamps-Latscha B, Kamoun P. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. Miner Electrolyte Metab. 1997;23(3-6):170-3.

Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 1999 Sep 14;100(11):1161-8.

Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991 Mar;48(3):536-45.

Kang SS, Passen EL, Ruggie N, Wong PW, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1993 Oct;88(4 Pt 1):1463-9.

Kardos A, Casadei B. Hormone replacement therapy and ischaemic heart disease among postmenopausal women. J Cardiovasc Risk. 1999 Apr;6(2):105-12. Review.

Kawashiri M, Kajinami K, Nohara A, Yagi K, Inazu A, Koizumi J, Haraki T, Takegoshi T, Mabuchi H. Plasma homocysteine level and development of coronary artery disease. Coron Artery Dis. 1999 Oct;10(7):443-7.

Keay KA, Crowfoot LJ, Floyd NS, Henderson LA, Christie MJ, Bandler R. Cardiovascular effects of microinjections of opioid agonists into the 'Depressor Region' of the ventrolateral periaqueductal gray region. Brain Res. 1997 Jul 11;762(1-2):61-71.

Khan MA, Thompson CS, Emsley AM, Mumtaz FH, Mikhailidis DP, Angelini GD, Morgan RJ, Jeremy JY. The interaction of homocysteine and copper markedly inhibits the relaxation of rabbit corpus cavernosum: new risk factors for angiopathic erectile dysfunction? BJU Int. 1999 Oct;84(6):720-4.

Kim JQ, Song J, Park YB, Hong SH. Molecular bases of coronary heart disease in Koreans. J Korean Med Sci. 1998 Feb;13(1):1-15.

Kim YI, Logan JW, Mason JB, Roubenoff R. DNA hypomethylation in inflammatory arthritis: reversal with methotrexate J Lab Clin Med. 1996 Aug;128(2):165-72.

300. Kim SS, Hirose S, Tamura H, Nagasawa R, Tokushima H, Mitarai T, Isoda K. Hyperhomocysteinemia as a possible role for atherosclerosis in CAPD patients. Adv Perit Dial. 1994;10:282-5.

Kircher T, Sinzinger H. [Hyperhomocysteinemia] Vasa. 1999 Nov;28(4):306. German.

Klevay LM. The homocysteine theory of arteriosclerosis. Nutr Rev. 1992 May;50(5):155.

Klor HU, Hauenschild A, Holbach I, Schnell-Kretschmer H, Stroh S. Nutrition and cardiovascular disease. Eur J Med Res. 1997 Jun 16;2(6):243-57.

Kluger J. Beyond cholesterol. Time. 1997 Aug 4;150(5):48.

Kluijtmans LA, Kastelein JJ, Lindemans J, Boers GH, Heil SG, Bruschke AV, Jukema JW, van den Heuvel LP, Trijbels FJ, Boerma GJ, Verheugt FW, Willems F, Blom HJ. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1997 Oct 21;96(8):2573-7.

Koch HG, Goebeler M, Marquardt T, Roth J, Harms E. The redox status of aminothiols as a clue to homocysteine-induced vascular damage? Eur J Pediatr. 1998 Apr;157 Suppl 2:S102-6.

Kokame K, Kato H, Miyata T. Nonradioactive differential display cloning of genes induced by homocysteine in vascular endothelial cells. Methods. 1998 Dec;16(4):434-43.

Konecky N, Malinow MR, Tunick PA, Freedberg RS, Rosenzweig BP, Katz ES, Hess DL, Upson B, Leung B, Perez J, Kronzon I. Correlation between plasma homocyst(e)ine and aortic atherosclerosis. Am Heart J. 1997 May;133(5):534-40.

Kostulas K, Crisby M, Huang WX, Lannfelt L, Hagenfeldt L, Eggertsen G, Kostulas V, Hillert J. A methylenetetrahydrofolate reductase gene polymorphism in ischaemic stroke and in carotid artery stenosis. Eur J Clin Invest. 1998 Apr;28(4):285-9.

Koyama J. [The influence of methionine and its metabolites on the progression of atherosclerosis in rabbits] Nippon Ika Daigaku Zasshi. 1995 Dec;62(6):596-604. Japanese.

Kroll K, Martin GV. Steady-state catecholamine stimulation does not increase cytosolic adenosine in canine hearts. Am J Physiol. 1994 Feb;266(2 Pt 2):H503-10.

Kroll K, Martin GV. Comparison of myocardial ATP, blood flow, and cytosolic adenosine in demand ischemia and coronary occlusion. Am J Physiol. 1995 Sep;269(3 Pt 2):H819-28.

Kronenberg F. Homocysteine, lipoprotein(a) and fibrinogen: metabolic risk factors for cardiovascular complications of chronic renal disease.Curr Opin Nephrol Hypertens. 1998 May;7(3):271-8.

Krogh Jensen M, Ekelund S, Svendsen L. Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. Scand J Clin Lab Invest. 1996 Aug;56(5):421-9.

Kuritzky L. Homocysteine as a risk factor for arteriosclerosis. Hosp Pract (Off Ed). 1996 Mar 15;31(3):37, 41.

Kwiterovich PO Jr. The effect of dietary fat, antioxidants, and pro-oxidants on blood lipids, lipoproteins, and atherosclerosis. J Am Diet Assoc. 1997 Jul;97(7 Suppl):S31-41.

Labanti G, Urbinati S, Grepioni A, Pinelli GL, Pinelli G. [Complicated atherosclerosis of the ascending aorta as a cause of recurrent cerebral embolisms in young adulthood] G Ital Cardiol. 1998 Dec;28(12):1418-21. Review. Italian.

Laghi Pasini F, De Franco V, Pieragalli D, Volpi L, Panti S, Petri S, Di Perri T. [Plasma levels of homocysteine and peripheral obliterating arteriopathies. An epidemiologic study of hospitalized patients] Minerva Cardioangiol. 1998 Sep;46(9):312. Italian.

Lambert J, van den Berg M, Steyn M, Rauwerda JA, Donker AJ, Stehouwer CD. Familial hyperhomocysteinaemia and endothelium-dependent vasodilatation and arterial distensibility of large arteries. Cardiovasc Res. 1999 Jun;42(3):743-51.

Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattstrom L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med. 1995 Apr;237(4):381-8.

Lalouschek W, Aull S, Deecke L, Schnider P, Uhl F, Zeiler K. [Hyperhomocyst(e)inemia--an independent risk factor of stroke] Fortschr Neurol Psychiatr. 1996 Jul;64(7):271-7. German.

Lalouschek W, Aull S, Serles W, Schnider P, Mannhalter C, Lang T, Deecke L, Zeiler K. Genetic and nongenetic factors influencing plasma homocysteine levels in patients with ischemic cerebrovascular disease and in healthy control subjects. J Lab Clin Med. 1999 Jun;133(6):575-82.

Larkin M. Kilmer McCully: pioneer of the homocysteine theory. Lancet. 1998 Oct 24;352(9137):1364.

Lavie CJ, Milani RV. Cardiac rehabilitation and preventive cardiology in the elderly. Cardiol Clin. 1999 Feb;17(1):233-42. Review.

Law MR, Wald NJ. Homocysteine and ischaemic heart disease. Haematologica. 1999 Jun;84 Suppl EHA-4:57-60. Review

Lee YK, Kwon YJ, Yoon JW, Oh KS, Cha DR, Cho WY, Huh K, Pyo HJ, Kim HK. Homocyst(e)ine and atherosclerosis in patients on chronic hemodialysis. J Korean Med Sci. 1999 Apr;14(2):193-8.

Lee ME, Wang H. Homocysteine and hypomethylation. A novel link to vascular disease. Trends Cardiovasc Med. 1999 Jan-Feb;9(1-2):49-54.

Lenhart SE, Nappi JM. Vitamins for the management of cardiovascular disease: a simple solution to a complex problem? Pharmacotherapy. 1999 Dec;19(12):1400-14. Review.

Lentz SR, Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood. 1993 Feb 1;81(3):683-9.

Lentz SR. Homocysteine and vascular dysfunction. Life Sci. 1997;61(13):1205-15.

Lentz SR, Fernandez JA, Griffin JH, Piegors DJ, Erger RA, Malinow MR, Heistad DD. Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system. Arterioscler Thromb Vasc Biol. 1999 Jul;19(7):1744-50.

Lentz SR, Malinow MR, Piegors DJ, Bhopatkar-Teredesai M, Faraci FM, Heistad DD. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2930-4.

Lewis CA, Pancharuniti N, Sauberlich HE. Plasma folate adequacy as determined by homocysteine level. Ann N Y Acad Sci. 1992 Sep 30;669:360-2.

Liangos O, Kreutz R, Beige J, Offermann G, Distler A, Sharma AM. Methylenetetrahydrofolate-reductase gene C677T variant and kidney-transplant survival. Nephrol Dial Transplant. 1998 Sep;13(9):2351-4.

Li W, Zheng T, Wang J, Altura BT, Altura BM. Extracellular magnesium regulates effects of vitamin B6, B12 and folate on homocysteinemia-induced depletion of intracellular free magnesium ions in canine cerebral vascular smooth muscle cells: possible relationship to [Ca2+]i, atherogenesis and stroke. Neurosci Lett. 1999 Oct 22;274(2):83-6.

Li Y, Chen X, Zhao X, Hu B. [Relationship between homocysteine-induced apoptosis and teratogenesis in developing avian embryo] Wei Sheng Yan Jiu. 1999 Sep 30;28(5):275-8. Chinese.

Lien EA, Anker G, Lonning PE, Refsum H, Ueland PM. Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochem Soc Trans. 1997 Feb;25(1):33-5.

Lien EA, Anker G, Lonning PE, Refsum H, Ueland PM. Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochem Soc Trans. 1997 Feb;25(1):33-5. Review.

Lilien M, Duran M, Van Hoeck K, Poll-The BT, Schroder C. Hyperhomocyst(e)inaemia in children with chronic renal failure.Nephrol Dial Transplant. 1999 Feb;14(2):366-8.

Lindgren A, Lindoff C, Norrving B, Astedt B, Johansson BB. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke. 1996 Jun;27(6):1066-71.

Liu T, Stern A, Roberts LJ, Morrow JD. The isoprostanes: novel prostaglandin-like products of the free radical-catalyzed peroxidation of arachidonic acid. J Biomed Sci. 1999 Jul-Aug;6(4):226-35.

Liu H, Gao R, Hui R, Chen J, Zhang C, Wu Y. [The association between plasma homocysteine and the number of coronary artery with stenosis] Zhonghua Nei Ke Za Zhi. 1999 Dec;38(12):821-3. Chinese.

Lobo A, Naso A, Arheart K, Kruger WD, Abou-Ghazala T, Alsous F, Nahlawi M, Gupta A, Moustapha A, van Lente F, Jacobsen DW, Robinson K. Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. Am J Cardiol. 1999 Mar 15;83(6):821-5.

Loehrer FM, Angst CP, Haefeli WE, Jordan PP, Ritz R, Fowler B. Low whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):727-33.

Loew D, Wanitschke R, Schroedter A. Studies on vitamin B12 status in the elderly--prophylactic and therapeutic consequences. Int J Vitam Nutr Res. 1999 May;69(3):228-33.

Lolin YI, Sanderson JE, Cheng SK, Chan CF, Pang CP, Woo KS, Masarei JR. Hyperhomocysteinaemia and premature coronary artery disease in the Chinese. Heart. 1996 Aug;76(2):117-22.

Loncar R, Flesche CW, Deussen A. Coronary reserve of high- and low-flow regions in the dog heart left ventricle. Circulation. 1998 Jul 21;98(3):262-70.

Lonn EM, Yusuf S. Emerging approaches in the prevention of atherosclerotic cardiovascular diseases. Int J Clin Pract Suppl. 1998 May;94:7-19.

Lubbers MF, Aarnoudse JG, van Doormaal JJ. [Obstetric problems followed by stroke] Ned Tijdschr Geneeskd. 1999 Apr 3;143(14):705-8. Dutch.

Luft FC. Homocyst(e)ine is bad for blood vessels, but how come? J Mol Med. 1996 Dec;74(12):705-6.

Lupattelli G, Rufini S, Locati EH, Lombardini R, Ciuffetti G, Siepi D, Mannarino E. Hyperhomocyst(e)inemia is associated with carotid atherosclerosis. Angiology. 1999 Oct;50(10):823-30.

Lutteri L, Chapelle JP, Gielen J. [Homocysteine and cardiovascular risk] Rev Med Liege. 1999 Jun;54(6):541-7. French.

Lynch SM, Frei B. Physiological thiol compounds exert pro- and anti-oxidant effects, respectively, on iron- and copper-dependent oxidation of human low-density lipoprotein. Biochim Biophys Acta. 1997 Apr 1;1345(2):215-21.

Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996 Nov 15;94(10):2410-6.

Magott M. [Homocysteine as a nonlipid factor in the pathogenesis of atherosclerosis] Postepy Hig Med Dosw. 1998;52(3):259-67. Polish.

Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):2074-81.

Malek AM, Izumo S, Alper SL. Modulation by pathophysiological stimuli of the shear stress-induced up-regulation of endothelial nitric oxide synthase expression in endothelial cells. Neurosurgery. 1999 Aug;45(2):334-44; discussion 344-5.

Malik NM, Syrris P, Schwartzman R, Kaski JC, Crossman DC, Francis SE, Carter ND, Jeffery S. Methylenetetrahydrofolate reductase polymorphism (C-677T) and coronary artery disease. Clin Sci (Lond). 1998 Sep;95(3):311-5.

Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, Block PC, Holzgang CR, Anderson PH, Seltzer D, Upson B, Lin QR. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1157-62.

Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med. 1994 Dec;236(6):603-17.

Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1999 Jan 5-12;99(1):178-82.

Malinow MR, Levenson J, Giral P, Nieto FJ, Razavian M, Segond P, Simon A. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis. 1995 Apr 24;114(2):175-83.

Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation. 1993 Apr;87(4):1107-13.

Malinow MR. Plasma homocyst(e)ine and arterial occlusive diseases: a mini-review. Clin Chem. 1995 Jan;41(1):173-6.

Malinow MR. Plasma homocyst(e)ine: a risk factor for arterial occlusive diseases. J Nutr. 1996 Apr;126(4 Suppl):1238S-43S.

Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, Gluckman RA, Block PC, Upson BM. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 1998 Apr 9;338(15):1009-15.

Malinow MR, Ducimetiere P, Luc G, Evans AE, Arveiler D, Cambien F, Upson BM. Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis. 1996 Sep 27;126(1):27-34.

Malinow MR, Axthelm MK, Meredith MJ, MacDonald NA, Upson BM. Synthesis and transsulfuration of homocysteine in blood. J Lab Clin Med. 1994 Mar;123(3):421-9.

Malinow MR. Homocyst(e)ine, vitamins and genetic interactions in vascular disease. Can J Cardiol. 1999 Apr;15 Suppl B:31B-34B.

Malinow MR. Hyperhomocyst(e)inemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation. 1990 Jun;81(6):2004-6.

Malinow MR, Stampfer MJ. Role of plasma homocyst(e)ine in arterial occlusive diseases. Clin Chem. 1994 Jun;40(6):857-8.

Mansoor MA. Hyperhomocysteinaemia and premature coronary artery disease in the Chinese. Heart. 1997 Apr;77(4):390.

Mansoor MA, Vefring H, Kristensen O. [Homocysteine--an independent risk factor of premature vascular disease] Tidsskr Nor Laegeforen. 1996 May 30;116(14):1663-7. Norwegian.

Mar MH, Zeisel SH. Betaine in wine: answer to the French paradox? Med Hypotheses. 1999 Nov;53(5):383-5.

Markle HV. Coronary artery disease associated with Helicobacter pylori infection is at least partially due to inadequate folate status. Med Hypotheses. 1997 Oct;49(4):289-92.

Markovic N, Stefanovic V. [Hyperhomocysteinemia--a risk factor in atherosclerosis] Srp Arh Celok Lek. 1999 Sep-Oct;127(9-10):326-32. Serbo-Croatian (Cyrillic).

Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke. 1997 Sep;28(9):1739-43.

Masser PA, Taylor LM Jr, Porter JM. Importance of elevated plasma homocysteine levels as a risk factor for atherosclerosis. Ann Thorac Surg. 1994 Oct;58(4):1240-6.

Mattaneo M. Homocysteine and cardiovascular diseases. Circulation. 1999 Dec 21;100(25):e151

Matthias D, Becker CH, Riezler R, Kindling PH. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis. 1996 May;122(2):201-16.

Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996 Mar 1;27(3):517-27.

Mazza A, Motti C, Nulli A, Pastore A, Andreotti F, Ammaturo V, Bianco P, Santoro E, Federici G, Cortese C. Serum homocysteine, MTHFR gene polymorphism, and carotid intimal-medial thickness in NIDDM subjects. J Thromb Thrombolysis. 1999 Oct;8(3):207-12.

McAuley DF, Hanratty CG, McGurk C, Nugent AG, Johnston GD. Effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidation. J Toxicol Clin Toxicol. 1999;37(4):435-40.

McCully KS, Olszewski AJ, Vezeridis MP. Homocysteine and lipid metabolism in atherogenesis: effect of the homocysteine thiolactonyl derivatives, thioretinaco and thioretinamide. Atherosclerosis. 1990 Aug;83(2-3):197-206.

McCully KS. Homocystinuria, arteriosclerosis, methylmalonic aciduria, and methyltransferase deficiency: a key case revisited. Nutr Rev. 1992 Jan;50(1):7-12.

McCully KS. Atherosclerosis, serum cholesterol and the homocysteine theory: a study of 194 consecutive autopsies. Am J Med Sci. 1990 Apr;299(4):217-21.

McCully KS. Chemical pathology of homocysteine. II. Carcinogenesis and homocysteine thiolactone metabolism. Ann Clin Lab Sci. 1994 Jan-Feb;24(1):27-59.

McCully KS. Chemical pathology of homocysteine. I. Atherogenesis. Ann Clin Lab Sci. 1993 Nov-Dec;23(6):477-93.

McCully KS. Homocysteine and vascular disease. Nat Med. 1996 Apr;2(4):386-9.

McKendry RJ. The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am. 1997 Nov;23(4):939-54. Review.

McQuillan BM, Beilby JP, Nidorf M, Thompson PL, Hung J. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS) Circulation. 1999 May 11;99(18):2383-8.

Medrano MJ, Barrado MJ, Almazan J. Is homocysteinaemia a risk factor for venous thrombosis and atherosclerotic vascular disease? Lancet. 1995 Jul 8;346(8967):127.

Mendis S, Athauda SB, Takashi K. Association between hyperhomocysteinemia and ischemic heart disease in Sri Lankans. Int J Cardiol. 1997 Dec 19;62(3):221-5.

Meleady RA, Graham IM. Homocysteine as a risk factor for coronary artery disease. J Cardiovasc Risk. 1995 Jun;2(3):216-21.

Meleady RA, Mulcahy DA, Graham IM. Genes, greens, and homocysteine. Heart. 1996 Aug;76(2):103-4.

Mendis S. Heart attacks: exploring new preventive strategies. Ceylon Med J. 1998 Dec;43(4):210-8.

Mercie P, Le Metayer P, Gosse P, Parrot F, Conri C. [Homocysteine in case of coronary disease] Presse Med. 1997 Jun 7;26(19):908. French.

Miner SE, Evrovski J, Cole DE. Clinical chemistry and molecular biology of homocysteine metabolism: an update. Clin Biochem. 1997 Apr;30(3):189-201.

Moghadasian MH, McManus BM, Frohlich JJ. Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med. 1997 Nov 10;157(20):2299-308. Review. Erratum in: Arch Intern Med 1998 Mar 23;158(6):662.

400. Molgaard J, Malinow MR, Lassvik C, Holm AC, Upson B, Olsson AG. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med. 1992 Mar;231(3):273-9.

Moll S. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997 Nov 27;337(22):1631-2; author reply 1632-3

Moller JM, Nielsen GL, Ekelund S, Schmidt EB, Dyerberg J. Homocysteine in Greenland Inuits. Thromb Res. 1997 May 15;86(4):333-5.

Monnerat C, Hayoz D. [Homocysteine and venous thromboembolism] Schweiz Med Wochenschr. 1997 Sep 6;127(36):1489-96. French.

Montalescot G. Homocysteine: the new player in the field of coronary risk. Heart. 1996 Aug;76(2):101-2.

Montalescot G, Ankri A, Chadefaux-Vekemans B, Blacher J, Philippe F, Drobinski G, Benzidia R, Kamoun P, Thomas D. Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. Int J Cardiol. 1997 Aug 8;60(3):295-300.

Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol. 1998 Mar;25(3):441-6.

Morgan SL, Baggott JE, Refsum H, Ueland PM. Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate. Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):547-56.

Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y. [Gene Polymorphism of 5, 10-methylenetetrahydrofolate reductase as a coronary risk factor] J Cardiol. 1997 Jun;29(6):309-15. Japanese.

Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997 Apr 15;95(8):2032-6.

Morita H, Kurihara H, Sugiyama T, Kitamura K, Suzuki S, Sumiyoshi T, Yazaki Y. [Genetic polymorphisms of methylenetetrahydrofolate reductase and methionine synthase: association with homocysteine metabolism and late-onset vascular diseases in the Japanese population] J Cardiol. 1999 Feb;33(2):106-7. Japanese.

Morita H, Kurihara H, Sugiyama T, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y. Polymorphism of the methionine synthase gene : association with homocysteine metabolism and late-onset vascular diseases in the Japanese population. Arterioscler Thromb Vasc Biol. 1999 Feb;19(2):298-302.

Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet. 1996 Jan;58(1):17-20.

Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998 Jan 20;97(2):138-41.

Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet. 1999 Jul 10;354(9173):126-7.

Murphy-Chutorian D, Alderman EL. The case that hyperhomocysteinemia is a risk factor for coronary artery disease. Am J Cardiol. 1994 Apr 1;73(9):705-7.

Najemnik C, Sinzinger H, Kritz H. Endothelial dysfunction, atherosclerosis and diabetes. Acta Med Austriaca. 1999;26(5):148-53.

Nakata Y, Katsuya T, Takami S, Sato N, Fu Y, Ishikawa K, Takiuchi S, Rakugi H, Miki T, Higaki J, Ogihara T. Methylenetetrahydrofolate reductase gene polymorphism: relation to blood pressure and cerebrovascular disease. Am J Hypertens. 1998 Aug;11(8 Pt 1):1019-23.

Naruszewicz M. [150 years of investigation of atherosclerosis--present status and perspectives] Pol Arch Med Wewn. 1997;97 Spec No:37-45. Polish.

Nasr A, Breckwoldt M. Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg. Gynecol Endocrinol. 1998 Feb;12(1):43-59.

Nedrebo BG, Ericsson UB, Nygard O, Refsum H, Ueland PM, Aakvaag A, Aanderud S, Lien EA. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism. 1998 Jan;47(1):89-93.

Nehler MR, Taylor LM Jr, Porter JM. Homocysteinemia as a risk factor for atherosclerosis: a review. Cardiovasc Surg. 1997 Dec;5(6):559-67.

Nesher G, Moore TL. The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthritis Rheum. 1990 Jul;33(7):954-9.

Neufeld EJ. Update on genetic risk factors for thrombosis and atherosclerotic vascular disease. Hematol Oncol Clin North Am. 1998 Dec;12(6):1193-209

Newman PE. Can reduced folic acid and vitamin B12 levels cause deficient DNA methylation producing mutations which initiate atherosclerosis? Med Hypotheses. 1999 Nov;53(5):421-4.

Ni W, Tsuda Y, Sakono M, Imaizumi K. Dietary soy protein isolate, compared with casein, reduces atherosclerotic lesion area in apolipoprotein E-deficient mice. J Nutr. 1998 Nov;128(11):1884-9.

Nichols TW Jr. Drug utilization. Pa Med. 1997 Oct;100(10):34-5.

Nieto FJ, Comstock GW, Chambless LE, Malinow RM. Coffee consumption and plasma homocyst(e)ine: results from the Atherosclerosis Risk in Communities Study. Am J Clin Nutr. 1997 Dec;66(6):1475-7.

Nishinaga M, Shimada K. [Heparan sulfate proteoglycan of endothelial cells: homocysteine suppresses anticoagulant active heparan sulfate in cultured endothelial cells] Rinsho Byori. 1994 Apr;42(4):340-5. Japanese.

Nishio E, Watanabe Y. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide. Br J Pharmacol. 1997 Sep;122(2):269-74.

Nordstrom M, Kjellstrom T. Age dependency of cystathionine beta-synthase activity in human fibroblasts in homocyst(e)inemia and atherosclerotic vascular disease. Atherosclerosis. 1992 Jun;94(2-3):213-21.

Nordstrom M, Kjellstrom T. Age and cystathionine beta-synthase activity in cultured fibroblasts from patients with arterial and venous vascular disease. Atherosclerosis. 1998 Aug;139(2):231-6.

Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 1995 Nov 15;274(19):1526-33.

Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997 Jul 24;337(4):230-6.

Nygard O, Refsum H, Ueland PM, Stensvold I, Nordrehaug JE, Kvale G, Vollset SE. Coffee consumption and plasma total homocysteine: The Hordaland Homocysteine Study. Am J Clin Nutr. 1997 Jan;65(1):136-43.

O'Connor DL, Green T, Picciano MF. Maternal folate status and lactation. J Mammary Gland Biol Neoplasia. 1997 Jul;2(3):279-89.

Okada E, Oida K, Tada H, Asazuma K, Eguchi K, Tohda G, Kosaka S, Takahashi S, Miyamori I. Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. Diabetes Care. 1999 Mar;22(3):484-90.

Okamura T, Kitamura A, Moriyama Y, Imano H, Sato S, Terao A, Naito Y, Nakagawa Y, Kiyama M, Tamura Y, Iida M, Suzuki H, Komachi Y. Plasma level of homocysteine is correlated to extracranial carotid-artery atherosclerosis in non-hypertensive Japanese. J Cardiovasc Risk. 1999 Dec;6(6):371-7.

Olinescu R, Kummerow FA, Handler B, Fleischer L. The hemolytic activity of homocysteine is increased by the activated polymorphonuclear leukocytes. Biochem Biophys Res Commun. 1996 Sep 24;226(3):912-6.

Olszewski AJ, Szostak WB, McCully KS. Plasma glucosamine and galactosamine in ischemic heart disease. Atherosclerosis. 1990 May;82(1-2):75-83.

Olszewski AJ, McCully KS. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med. 1993 Jun;14(6):683-93.

Olszewski AJ. Homocysteine content of plasma in ischemic heart disease, the reducing effect of pyridoxine, folate, cobalamin, choline, riboflavin and troxerutin. Correction of a calculation error. Atherosclerosis. 1991 May;88(1):97-8.

Olszewski AJ, McCully KS. Fish oil decreases serum homocysteine in hyperlipemic men. Coron Artery Dis. 1993 Jan;4(1):53-60.

Olszewski AJ, McCully KS. Homocysteine content of lipoproteins in hypercholesterolemia. Atherosclerosis. 1991 May;88(1):61-8.

Omenn GS, Beresford SA, Motulsky AG. Preventing coronary heart disease: B vitamins and homocysteine. Circulation. 1998 Feb 10;97(5):421-4.

Oparil S, Oberman A. Nontraditional cardiovascular risk factors. Am J Med Sci. 1999 Mar;317(3):193-207.

Ou T, Yamakawa-Kobayashi K, Arinami T, Amemiya H, Fujiwara H, Kawata K, Saito M, Kikuchi S, Noguchi Y, Sugishita Y, Hamaguchi H. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis. 1998 Mar;137(1):23-8.

Oxley DK. Hyperhomocysteinemia. Am J Clin Pathol. 1997 Jul;108(1):115.

Pahor M, Elam MB, Garrison RJ, Kritchevsky SB, Applegate WB. Emerging noninvasive biochemical measures to predict cardiovascular risk. Arch Intern Med. 1999 Feb 8;159(3):237-45.

Pancharuniti N, Lewis CA, Sauberlich HE, Perkins LL, Go RC, Alvarez JO, Macaluso M, Acton RT, Copeland RB, Cousins AL, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr. 1994 Apr;59(4):940-8. Erratum in: Am J Clin Nutr 1996 Apr;63(4):609.

Parhofer K, Schwandt P. [Increased homocysteine level--a risk factor for myocardial infarct?] Med Monatsschr Pharm. 1993 Nov;16(11):336-7. German.

Parnetti L, Bottiglieri T, Lowenthal D. Role of homocysteine in age-related vascular and non-vascular diseases. Aging (Milano). 1997 Aug;9(4):241-57.

Parodi PW. The French paradox unmasked: the role of folate. Med Hypotheses. 1997 Oct;49(4):313-8.

Perna AF, Castaldo P, Ingrosso D, De Santo NG. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. J Nephrol. 1999 Jul-Aug;12(4):230-40. Review.

Perry IJ. Serum total homocysteine concentration and risk of stroke. Lancet. 1996 Nov 30;348(9040):1526.

Perry IJ. Homocysteine and risk of stroke. J Cardiovasc Risk. 1999 Aug;6(4):235-40. Review.

Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet. 1998 Jan 24;351(9098):263.

Pettersson T, Friman C, Abrahamsson L, Nilsson B, Norberg B. Serum homocysteine and methylmalonic acid in patients with rheumatoid arthritis and cobalaminopenia. J Rheumatol. 1998 May;25(5):859-63.

Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol. 1996;25(4):191-3.

Pietrzik K, Bronstrup A. The role of homocysteine, folate and other B-vitamins in the development of atherosclerosis. Arch Latinoam Nutr. 1997 Jun;47(2 Suppl 1):9-12.

Pietrzik K, Bronstrup A. Causes and consequences of hyperhomocyst(e)inemia. Int J Vitam Nutr Res. 1997;67(5):389-95.

Pilgeram L. Perspective: a mechanism underlying homocysteinemia and increased risk of coronary artery and cerebrovascular disease. Circulation. 1996 Dec 1;94(11):2990.

Piolot A, Nadler F, Parez N, Jacotot B. [Homocysteine: relations to ischemic cardiovascular diseases] Rev Med Interne. 1996;17(1):34-45. French.

Por CP, Evans MF. Homocysteine. Is it a modifiable risk factor for patients with coronary artery disease? Can Fam Physician. 1998 Nov;44:2409-11.

Powers RW, Evans RW, Majors AK, Ojimba JI, Ness RB, Crombleholme WR, Roberts JM. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol. 1998 Dec;179(6 Pt 1):1605-11.

Prasad K. Homocysteine, a Risk Factor for Cardiovascular Disease. Int. J. Angiol.. 1999 Jan;8(1):76-86.

Pruefer D, Scalia R, Lefer AM. Homocysteine provokes leukocyte-endothelium interaction by downregulation of nitric oxide. Gen Pharmacol. 1999 Dec;33(6):487-98.

Puddu P. Homocysteine and risk for atherothrombotic events.Cardiologia. 1999 Jul;44(7):627-31. Review.

Raal FJ, Pilcher GJ, Waisberg R, Buthelezi EP, Veller MG, Joffe BI. Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. Am J Cardiol. 1999 May 1;83(9):1330-3.

Rafter GW. Plasma thiols, copper and rheumatoid arthritis. Med Hypotheses. 1994 Jul;43(1):59-61.

Raghavan M, Lebron JA, Johnson JL, Bjorkman PJ. Extended repertoire of permissible peptide ligands for HLA-B*2702. Protein Sci. 1996 Oct;5(10):2080-8.

Rajkumar V, Ragatzki P, Sima A, Levy J. Enhanced platelet aggregation, high homocysteine level, and microvascular disease in diabetic muscle infarctions: implications for therapy. Endocrine. 1999 Aug;11(1):57-60.

Rao AV. Coronary heart disease risk factors in women: focus on gender differences. J La State Med Soc. 1998 Feb;150(2):67-72.

Rath D, Chlumsky J, Potuznik P, Sprongl L, Prusa R, Hlavacek K. [Plasma homocysteine levels in patients with indications for cardiac revascularization] Vnitr Lek. 1998 May;44(5):255-8. Czech.

Rauwerda JA, Kluft C, Stehouwert CD. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest. 1995 Mar;25(3):176-81.

Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31-62.

Reinhardt D, Sigusch HH, Vogt SF, Farker K, Muller S, Hoffmann A. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease. Eur J Clin Invest. 1998 Jan;28(1):20-3.

Reis RP, Azinheira J, Reis HP, Vilaverde MM, Bordalo e Sa A, Santos L, Adao M, Pina JE, Ferreira NC, Luis AS. [Homocysteinemia as a risk factor for early myocardial infarct--a case-control study] Rev Port Cardiol. 1994 Feb;13(2):119-24, 103. Portuguese.

Reis RP, Azinheira J, Reis HP, Vilaverde MM, Bordalo e Sa AL, Santos L, Adao M, Pina JE, Ferreira NC, Luis AS. [Homocysteinemia as a risk factor for myocardial infarct--the importance of age and of the homocysteinemia levels] Rev Port Cardiol. 1995 Oct;14(10):713-6. Portuguese.

Reis RP, Azinheira J, Reis HP, Bordalo-Sa AL, Santos L, Adao M, Pina JE, Correia JM, Luis AS. [Basal homocysteinemia or following a methionine load. Which is the better indicator of coronary disease risk?] Rev Port Cardiol. 1996 Dec;15(12):939-42. Portuguese.

Reis RP, Luis AS. [Homocysteinemia and coronary artery disease] Rev Port Cardiol. 1995 Jul-Aug;14(7-8):521-3. Portuguese.

Reis RP, Azinheira J, Reis HP, Bordalo A, Santos L, Adao M, Pina JE, Ferreira NC, Luis AS. Homocysteinaemia after methionine overload as a coronary artery disease risk factor: importance of age and homocysteine levels. Coron Artery Dis. 1995 Nov;6(11):851-6.

Reis RP, Luis AS. [Homocysteinemia and vascular disease--a new risk factor is born] Rev Port Cardiol. 1999 May;18(5):507-14. Portuguese.

Rekhter MD. Collagen synthesis in atherosclerosis: too much and not enough. Cardiovasc Res. 1999 Feb;41(2):376-84.

Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA. 1999 May 19;281(19):1817-21.

Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998 Jan 10;351(9096):88-92.

Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med. 1999 Jun 1;130(11):933-7.

Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol. 1998;16(1):5-15.

Robillon JF, Canivet B, Candito M, Sadoul JL, Jullien D, Morand P, Chambon P, Freychet P. Type 1 diabetes mellitus and homocyst(e)ine. Diabete Metab. 1994 Sep-Oct;20(5):494-6.

Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchant K, Savon SR, Selhub J, Nissen SE, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation. 1995 Nov 15;92(10):2825-30.

Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchant K, Savon SR, Selhub J, Nissen SE, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation. 1995 Nov 15;92(10):2825-30.

Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation. 1996 Dec 1;94(11):2743-8.

Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, Ueland P, Rubba P, Palma-Reis R, Meleady R, Daly L, Witteman J, Graham I. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation. 1998 Feb 10;97(5):437-43. Erratum in: Circulation 1999 Feb 23;99(7):983.

Robinson K, Mayer E, Jacobsen DW. Homocysteine and coronary artery disease. Cleve Clin J Med. 1994 Nov-Dec;61(6):438-50.

Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990 Feb 15;75(4):895-901.

Rohde LE, Lee RT, Rivero J, Jamacochian M, Arroyo LH, Briggs W, Rifai N, Libby P, Creager MA, Ridker PM. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 1998 Nov;18(11):1765-70.

Rohde LE, Hennekens CH, Ridker PM. Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterioscler Thromb Vasc Biol. 1999 Jul;19(7):1595-9.

Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15227-32.

Rothkopf MM, Franco A, Usiskin K, Haverstick L, Malone M. Improvement of coronary artery disease in a patient with hyperhomocysteinemia: report of a case. Nutrition. 1998 Sep;14(9):687-90.

Roubenoff R, Dellaripa P, Nadeau MR, Abad LW, Muldoon BA, Selhub J, Rosenberg IH. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum. 1997 Apr;40(4):718-22.

500. Sacco RL, Wolf PA, Gorelick PB. Risk factors and their management for stroke prevention: outlook for 1999 and beyond. Neurology. 1999;53(7 Suppl 4):S15-24.

Sacco RL, Roberts JK, Jacobs BS. Homocysteine as a risk factor for ischemic stroke: an epidemiological story in evolution. Neuroepidemiology. 1998;17(4):167-73

Sakurabayashi T, Fujimoto M, Takaesu Y, Haginoshita S, Goto S, Aoike I, Miyazaki S, Koda Y, Yuasa Y, Sakai S, Suzuki M, Hirasawa Y. Association between plasma homocysteine concentration and carotid atherosclerosis in hemodialysis patients. Jpn Circ J. 1999 Sep;63(9):692-6.

Salamanca-Gomez F. [New risk factors for cardiovascular diseases] Gac Med Mex. 1997 Sep-Oct;133(5):481-2. Spanish.

Salooja N, Catto A, Carter A, Tudenham EG, Grant PJ. Methylene tetrahydrofolate reductase C677T genotype and stroke. Clin Lab Haematol. 1998 Dec;20(6):357-61.

Samani NJ. Methylenetetrahydrofolate reductase mutation and coronary artery disease. Circulation. 1998 Dec 22-29;98(25):2932-3.

Samuelsson O, Lee DM, Attman PO, Knight-Gibson C, Mullen JK, Larsson R, Mulec H, Weiss L, Alaupovic P. The plasma levels of homocysteine are elevated in moderate renal insufficiency but do not predict the rate of progression. Nephron. 1999;82(4):306-11.

Sankaranarayanan K, Chakraborty R, Boerwinkle EA. Ionizing radiation and genetic risks. VI. Chronic multifactorial diseases: a review of epidemiological and genetical aspects of coronary heart disease, essential hypertension and diabetes mellitus. Mutat Res. 1999 Jan;436(1):21-57.

Sarkar PK, Lambert L. Can lowering homocysteine levels reduce the incidence of stroke? J Clin Pharm Ther. 1999 Oct;24(5):331-8. Review. Erratum in: J Clin Pharm Ther 2000 Feb;25(1):75.

Saxena V, Markus H, Swaminathan S, Mendall ME. Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease. Heart. 1997 Nov;78(5):524.

Schachinger V, Britten MB, Elsner M, Walter DH, Scharrer I, Zeiher AM. A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation. Circulation. 1999 Oct 5;100(14):1502-8.

Schwaninger M, Ringleb P, Winter R, Kohl B, Fiehn W, Rieser PA, Walter-Sack I. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia. 1999 Mar;40(3):345-50.

Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, Psaty BM, Longstreth WT Jr, Koepsell TD, Raghunathan TE, Reitsma PH. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation. 1997 Jul 15;96(2):412-7.

Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study. Circulation. 1996 Oct 15;94(8):1812-4.

Scott CH, Sutton MS. Homocysteine: evidence for a causal relationship with cardiovascular disease. Cardiol Rev. 1999 Mar-Apr;7(2):101-7.

Sela B. [Hyperhomocysteinemia as a risk factor in atherosclerotic and thrombotic vascular processes] Harefuah. 1995 Nov 15;129(10):407-12. Hebrew.

Seman LJ, McNamara JR, Schaefer EJ. Lipoprotein(a), homocysteine, and remnantlike particles: emerging risk factors.Curr Opin Cardiol. 1999 Mar;14(2):186-91.

Seshadri N, Robinson K. Homocysteine and coronary risk. Curr Cardiol Rep. 1999 Jul;1(2):91-8.

Shankar R, de la Motte CA, DiCorleto PE. 3-Deazaadenosine inhibits thrombin-stimulated platelet-derived growth factor production and endothelial-leukocyte adhesion molecule-1-mediated monocytic cell adhesion in human aortic endothelial cells. J Biol Chem. 1992 May 5;267(13):9376-82.

Shimakawa T, Nieto FJ, Malinow MR, Chambless LE, Schreiner PJ, Szklo M. Vitamin intake: a possible determinant of plasma homocyst(e)ine among middle-aged adults. Ann Epidemiol. 1997 May;7(4):285-93.

Shinnick MA, Holmes LI. Coronary artery disease and homocysteine: a case study. Am J Crit Care. 1999 May;8(3):193-6.

Silberberg J, Crooks R, Fryer J, Wlodarczyk J, Nair B, Guo XW, Xie LJ, Dudman N. Gender differences and other determinants of the rise in plasma homocysteine after L-methionine loading. Atherosclerosis. 1997 Aug;133(1):105-10.

Simon J, Racek J, Rosolova H. [Homocysteine, a less well-known risk factor in cardiac and vascular diseases] Cas Lek Cesk. 1996 May 2;135(9):263-5. Czech.

Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol. 1999 Oct;15(9):773-81.

Siri PW, Verhoef P, Kok FJ. Vitamins B6, B12, and folate: association with plasma total homocysteine and risk of coronary atherosclerosis. J Am Coll Nutr. 1998 Oct;17(5):435-41.

Sobra J. [Hyperhomocysteinemia] Cas Lek Cesk. 1996 May 2;135(9):266-9. Czech.

Spence JD, Malinow MR, Barnett PA, Marian AJ, Freeman D, Hegele RA. Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area. Stroke. 1999 May;30(5):969-73.

Spence JD, Barnett PA, Bulman DE, Hegele RA. An approach to ascertain probands with a non-traditional risk factor for carotid atherosclerosis. Atherosclerosis. 1999 Jun;144(2):429-34.

Spence JD, Cordy P, Kortas C, Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Am J Nephrol. 1999;19(3):405-10.

Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992 Aug 19;268(7):877-81.

Stamler JS, Loscalzo J. Endothelium-derived relaxing factor modulates the atherothrombogenic effects of homocysteine. J Cardiovasc Pharmacol. 1992;20 Suppl 12:S202-4.

Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993 Jan;91(1):308-18.

Stehouwer CD, Gall MA, Hougaard P, Jakobs C, Parving HH. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int. 1999 Jan;55(1):308-14.

Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol. 1998 Dec;18(12):1895-901

Stehouwer CD, Jakobs C. Abnormalities of vascular function in hyperhomocysteinaemia: relationship to atherothrombotic disease. Eur J Pediatr. 1998 Apr;157 Suppl 2:S107-11.

Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. off. Arch Intern Med. 1998 Jun 22;158(12):1301-6.

Stern JM, Saver JL, Boldy RM, DeGregorio F. Homocysteine associated hypercoagulability and disseminated thrombosis--a case report. Angiology. 1998 Sep;49(9):765-9.

Still RA, McDowell IF. ACP Broadsheet No 152: March 1998. Clinical implications of plasma homocysteine measurement in cardiovascular disease. J Clin Pathol. 1998 Mar;51(3):183-8.

Stork S, Angerer P, von Schacky C. [Hyperhomocysteinemia: a new risk factor for atherosclerosis] Dtsch Med Wochenschr. 1997 Jan 3;122(1-2):1-2. Review. German.

Stolzenberg-Solomon RZ, Miller ER 3rd, Maguire MG, Selhub J, Appel LJ. Association of dietary protein intake and coffee consumption with serum homocysteine concentrations in an older population. Am J Clin Nutr. 1999 Mar;69(3):467-75.

Stone DH, McCarron P, Smith GD. Similarities in the epidemiology of neural tube defects and coronary heart disease: is homocysteine the missing link? J Epidemiol Community Health. 1999 Dec;53(12):789-93.

Stoney CM. Plasma homocysteine levels increase in women during psychological stress. Life Sci. 1999;64(25):2359-65.

Strachan DP. Non-gastrointestinal consequences of Helicobacter pylori infection. Br Med Bull. 1998;54(1):87-93.

Sung JJ, Sanderson JE. Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease. Heart. 1996 Oct;76(4):305-7.

Superko HR. Lipid disorders contributing to coronary heart disease: an update. Curr Probl Cardiol. 1996 Nov;21(11):736-80.

Superko HR. New aspects of risk factors for the development of atherosclerosis, including small low-density lipoprotein, homocyst(e)ine, and lipoprotein(a). Curr Opin Cardiol. 1995 Jul;10(4):347-54.

Superko HR. Elevated high-density lipoprotein cholesterol, not protective in the presence of homocysteinemia. Am J Cardiol. 1997 Mar 1;79(5):705-6.

Suter PM, Hasler E, Locher R, Vetter W. [Homocysteine: a cardiovascular risk factor?] Schweiz Rundsch Med Prax. 1999 Feb 11;88(7):259-72. German.

Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation. 1997 Sep 16;96(6):1745-9.

Swain RA, St Clair L. The role of folic acid in deficiency states and prevention of disease. J Fam Pract. 1997 Feb;44(2):138-44.

Taha S, Azzi A, Ozer NK. Homocysteine induces DNA synthesis and proliferation of vascular smooth muscle cells by a hydrogen peroxide-independent mechanism. Antioxid Redox Signal. 1999 Fall;1(3):365-9.

Tang L, Mamotte CD, Van Bockxmeer FM, Taylor RR. The effect of homocysteine on DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis. 1998 Jan;136(1):169-73.

Taoka S, West M, Banerjee R. Characterization of the heme and pyridoxal phosphate cofactors of human cystathionine beta-synthase reveals nonequivalent active sites. Biochemistry. 1999 Mar 2;38(9):2738-44. Erratum in: Biochemistry 1999 Jun 1;38(22):7406.

Takeya H, Suzuki K. [Coagulation and fibrinolytic systems and atherogenesis] Nippon Rinsho. 1993 Aug;51(8):1998-2003. Japanese.

Takeya H, Suzuki K. [Anticoagulant and fibrinolytic systems of the injured vascular endothelial cells] Rinsho Byori. 1994 Apr;42(4):333-9. Japanese.

Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997 Mar 4;95(5):1119-21.

Taylor LM Jr, DeFrang RD, Harris EJ Jr, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg. 1991 Jan;13(1):128-36.

Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg. 1999 Jan;29(1):8-19; discussion 19-21.

Taylor LM Jr, Porter JM. Elevated plasma homocysteine as a risk factor for atherosclerosis. Semin Vasc Surg. 1993 Mar;6(1):36-45.

Titus K. A panorama of cardiac risk. CAP Today. 1999 Feb;13(2):1, 18-20, 22 passim.

Toborek M, Kopieczna-Grzebieniak E, Drozdz M, Wieczorek M. Increased lipid peroxidation as a mechanism of methionine-induced atherosclerosis in rabbits. Atherosclerosis. 1995 Jun;115(2):217-24.

Todesco L, Angst C, Litynski P, Loehrer F, Fowler B, Haefeli WE. Methylenetetrahydrofolate reductase polymorphism, plasma homocysteine and age. Eur J Clin Invest. 1999 Dec;29(12):1003-9.

Tokgozoglu SL, Alikasifoglu M, Unsal, Atalar E, Aytemir K, Ozer N, Ovunc K, Usal O, Kes S, Tuncbilek E. Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate. Heart. 1999 May;81(5):518-22.

Tonstad S, Joakimsen O, Stensland-Bugge E, Leren TP, Ose L, Russell D, Bonaa KH. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol. 1996 Aug;16(8):984-91.

Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine beta-synthase gene. Am J Hum Genet. 1996 Dec;59(6):1262-7.

Tsai MY, Welge BG, Hanson NQ, Bignell MK, Vessey J, Schwichtenberg K, Yang F, Bullemer FE, Rasmussen R, Graham KJ. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases. Atherosclerosis. 1999 Mar;143(1):163-70.

Tsai MY. Laboratory assessment of mild hyperhomocysteinemia as an independent risk factor for occlusive vascular diseases. Clin Chem. 1996 Apr;42(4):492-3.

Tsai JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NE, Tan LC, Haber E, Chang TH, Schlegel R, Lee ME. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest. 1996 Jan 1;97(1):146-53.

Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6369-73.

Tucker KL, Mahnken B, Wilson PW, Jacques P, Selhub J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. JAMA. 1996 Dec 18;276(23):1879-85.

Turgan N, Boydak B, Habif S, Apakkan S, Ozmen D, Mutaf I, Bayindir O. Plasma homocysteine levels in acute coronary syndromes. Jpn Heart J. 1999 Nov;40(6):729-36.

Turner SL, Bechtel GA. Homocysteine and the heart. Adv Nurse Pract. 1999 Mar;7(3):71-3.

Tyagi SC, Smiley LM, Mujumdar VS, Clonts B, Parker JL. Reduction-oxidation (Redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone. Mol Cell Biochem. 1998 Apr;181(1-2):107-16.

Tyagi SC. Homocyst(e)ine and heart disease: pathophysiology of extracellular matrix. Clin Exp Hypertens. 1999 Apr;21(3):181-98.

Tyagi SC. Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am J Physiol. 1998 Feb;274(2 Pt 1):C396-405.

Ubbink JB, Vermaak WJ, Bennett JM, Becker PJ, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr. 1991 Aug 16;69(12):527-34.

Ubbink JB. Homocysteine--an atherogenic and a thrombogenic factor? Nutr Rev. 1995 Nov;53(11):323-5.

Ubbink JB. Should all elderly people receive folate supplements? Drugs Aging. 1998 Dec;13(6):415-20.

Ubbink JB. Vitamin nutrition status and homocysteine: an atherogenic risk factor. Nutr Rev. 1994 Nov;52(11):383-7.

Ubbink JB, Fehily AM, Pickering J, Elwood PC, Vermaak WJ. Homocysteine and ischaemic heart disease in the Caerphilly cohort. Atherosclerosis. 1998 Oct;140(2):349-56.

Ubbink JB, Becker PJ, Vermaak WJ, Delport R. Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine. Clin Chem. 1995 Jul;41(7):1033-7.

Ubbink JB, Vermaak WJ, Delport R, van der Merwe A, Becker PJ, Potgieter H. Effective homocysteine metabolism may protect South African blacks against coronary heart disease. Am J Clin Nutr. 1995 Oct;62(4):802-8.

Ubbink JB, Delport R, Vermaak WJ. Plasma homocysteine concentrations in a population with a low coronary heart disease prevalence. J Nutr. 1996 Apr;126(4 Suppl):1254S-7S.

Ungvari Z, Pacher P, Rischak K, Szollar L, Koller A. Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia. Arterioscler Thromb Vasc Biol. 1999 Aug;19(8):1899-904.

Upchurch GR Jr, Welch GN, Fabian AJ, Pigazzi A, Keaney JF Jr, Loscalzo J. Stimulation of endothelial nitric oxide production by homocyst(e)ine. Atherosclerosis. 1997 Jul 25;132(2):177-85.

Valentine RJ, Kaplan HS, Green R, Jacobsen DW, Myers SI, Clagett GP. Lipoprotein (a), homocysteine, and hypercoagulable states in young men with premature peripheral atherosclerosis: a prospective, controlled analysis. J Vasc Surg. 1996 Jan;23(1):53-61, discussion 61-3.

van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 1997 Jan 7;95(1):21-3.

van den Berg M, Franken DG, Boers GH, Blom HJ, Jakobs C, Stehouwer CD, Rauwerda JA. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia.J Vasc Surg. 1994 Dec;20(6):933-40.

van den Berg M, Stehouwer CD, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):165-71.

van den Berg M, van der Knaap MS, Boers GH, Stehouwer CD, Rauwerda JA, Valk J. Hyperhomocysteinaemia; with reference to its neuroradiological aspects. Neuroradiology. 1995 Jul;37(5):403-11.

van der Griend R, Meuwissen OJ. [Hyperhomocysteinemia as risk factor for premature atherosclerosis] Ned Tijdschr Geneeskd. 1994 Feb 26;138(9):456-9. Dutch.

van der Griend R, Haas FJ, Biesma DH, Duran M, Meuwissen OJ, Banga JD. Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinaemia in patients with premature arterial disease and their relatives. Atherosclerosis. 1999 Mar;143(1):177-83.

van der Griend R, Haas FJ, Duran M, Biesma DH, Meuwissen OJ, Banga JD. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med. 1998 Jul;132(1):67-72.

van der Molen EF, Hiipakka MJ, van Lith-Zanders H, Boers GH, van den Heuvel LP, Monnens LA, Blom HJ. Homocysteine metabolism in endothelial cells of a patient homozygous for cystathionine beta-synthase (CS) deficiency. Thromb Haemost. 1997 Aug;78(2):827-33.

van der Mooren MJ, Mijatovic V, van Baal WM, Stehouwer CD. Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease. Maturitas. 1998 Sep 20;30(1):27-36.

van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998 Apr;27(5):277-92.

van Guldener C, Lambert J, Janssen MJ, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant. 1997;12 Suppl 2:14-8.

van Guldener C, Janssen MJ, Lambert J, Steyn M, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant. 1998 Jul;13(7):1782-6.

van Leeuwen-Wintjens HR, Muls EE. The implications of hyperhomocysteinemia in a patient with type 1 diabetes. Acta Clin Belg. 1998 Oct;53(5):349-52.

Ventura P, Panini R, Pasini MC, Scarpetta G, Salvioli G. N -Acetyl-cysteine reduces homocysteine plasma levels after single intravenous administration by increasing thiols urinary excretion. Pharmacol Res. 1999 Oct;40(4):345-50.

600. Verhaeghe R. [Epidemiology and prognosis of peripheral obliterative arteriopathy] Drugs. 1998;56 Suppl 3:1-10. French.

Verhoef P, Kok FJ, Kruyssen DA, Schouten EG, Witteman JC, Grobbee DE, Ueland PM, Refsum H. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1997 May;17(5):989-95.

Verhoef P, Stampfer MJ, Rimm EB. Folate and coronary heart disease. Curr Opin Lipidol. 1998 Feb;9(1):17-22.

Verhoef P, Rimm EB, Hunter DJ, Chen J, Willett WC, Kelsey K, Stampfer MJ. A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: results among U.S. men. J Am Coll Cardiol. 1998 Aug;32(2):353-9.

Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, Reynolds RD, Kok FJ, Hennekens CH, Willett WC. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol. 1996 May 1;143(9):845-59.

Verhoef P, Kok FJ, Kluijtmans LA, Blom HJ, Refsum H, Ueland PM, Kruyssen DA. The 677C-->T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis. 1997 Jul 11;132(1):105-13.

Verhoeff BJ, Trip MD, Prins MH, Kastelein JJ, Reitsma PH. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis. 1998 Nov;141(1):161-6.

Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994 Oct;25(10):1924-30.

Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stampfer MJ. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol. 1997 Mar 15;79(6):799-801.

Vermaak WJ, Ubbink JB, Delport R, Becker PJ, Bissbort SH, Ungerer JP. Ethnic immunity to coronary heart disease? Atherosclerosis. 1991 Aug;89(2-3):155-62.

Vilaseca MA, Moyano D, Artuch R, Ferrer I, Pineda M, Cardo E, Campistol J, Pavia C, Camacho JA. Selective screening for hyperhomocysteinemia in pediatric patients. Clin Chem. 1998 Mar;44(3):662-4.

von Eckardstein A, Malinow MR, Upson B, Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb. 1994 Mar;14(3):460-4.

von Eckardstein A, Assmann G. [Homocysteine and atherogenesis] Internist (Berl). 1998 Feb;39(2):214-5. German.

von Eckardstein A, Assmann G. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997 Nov 27;337(22):1632-3.

Voutilainen S, Alfthan G, Nyyssonen K, Salonen R, Salonen JT. Association between elevated plasma total homocysteine and increased common carotid artery wall thickness. Ann Med. 1998 Jun;30(3):300-6.

Voutilainen S, Morrow JD, Roberts LJ 2nd, Alfthan G, Alho H, Nyyssonen K, Salonen JT. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vasc Biol. 1999 May;19(5):1263-6.

Wang J, Dudman NP, Wilcken DE, Lynch JF. Homocysteine catabolism: levels of 3 enzymes in cultured human vascular endothelium and their relevance to vascular disease. Atherosclerosis. 1992 Nov;97(1):97-106.

Wang XL, Cai H, Cranney G, Wilcken DE. The frequency of a common mutation of the methionine synthase gene in the Australian population and its relation to smoking and coronary artery disease. J Cardiovasc Risk. 1998 Oct-Dec;5(5-6):289-95.

Wanner C, Zimmermann J. Causes of coronary heart disease in patients on renal replacement therapy. Kidney Blood Press Res. 1998;21(2-4):287-9.

Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med. 1998 Apr 27;158(8):862-7.

Wautrecht JC. [Hyperhomocysteinemia: risk factor for premature atheromatosis] Rev Med Brux. 1997 Jun;18(3):103-6. French.

Welch GN, Upchurch G Jr, Loscalzo J. Hyperhomocyst(e)inemia and atherothrombosis. Ann N Y Acad Sci. 1997 Apr 15;811:48-58; discussion 58-9.

Welch GN, Upchurch GR Jr, Loscalzo J. Homocysteine, oxidative stress, and vascular disease. Hosp Pract (Off Ed). 1997 Jun 15;32(6):81-2, 85, 88-92.

Weiss N, Feussner A, Hailer S, Spengel FA, Keller C, Wolfram G. Influence of folic acid, pyridoxal phosphate and cobalamin on plasma homocyst(e)ine levels and the susceptibility of low-density lipoprotein to ex-vivo oxidation. Eur J Med Res. 1999 Oct 15;4(10):425-32.

Weiss N, Pietrzik K, Keller C. [Hyperhomocysteinemia, a risk factor for atherosclerosis: causes and effects] Dtsch Med Wochenschr. 1999 Sep 24;124(38):1107-13. Review. German.

Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998 Apr 9;338(15):1042-50.

Welch GN, Upchurch GR Jr, Farivar RS, Pigazzi A, Vu K, Brecher P, Keaney JF Jr, Loscalzo J. Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NF-kappa B-dependent transcriptional activation of Nos2. Proc Assoc Am Physicians. 1998 Jan-Feb;110(1):22-31.

Westhuyzen J. Folate supplementation in the dialysis patient--fragmentary evidence and tentative recommendations. Nephrol Dial Transplant. 1998 Nov;13(11):2748-50.

Whincup PH, Mendall MA, Perry IJ, Strachan DP. Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease. Heart. 1997 Nov;78(5):524.

Wilcken DE, Wang XL, Wilcken B. Methylenetetrahydrofolate reductase (MTHFR) mutation, homocyst(e)ine, and coronary artery disease. Circulation. 1997 Oct 21;96(8):2738-40.

Wilson PW. Metabolic risk factors for coronary heart disease: current and future prospects. Curr Opin Cardiol. 1999 Mar;14(2):176-85. Review.

Wilson PW, Culleton BF. Epidemiology of cardiovascular disease in the United States. Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S56-65.

Wolf PA. Prevention of stroke. Lancet. 1998 Oct;352 Suppl 3:SIII15-8.

Wollesen F, Dahlen G, Berglund L, Berne C. Peripheral atherosclerosis and serum lipoprotein(a) in diabetes. Diabetes Care. 1999 Jan;22(1):93-8.

Wolos JA, Frondorf KA, Esser RE. Immunosuppression mediated by an inhibitor of S-adenosyl-L-homocysteine hydrolase. Prevention and treatment of collagen-induced arthritis. J Immunol. 1993 Jul 1;151(1):526-34.

Woo KS, Chook P, Young RP, Sanderson JE. New risk factors for coronary heart disease in Asia. Int J Cardiol. 1997 Dec 1;62 Suppl 1:S39-42

Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997 Oct 21;96(8):2542-4.

Woodside JV, Young IS, Yarnell JW, Roxborough HE, McMaster D, McCrum EE, Gey KF, Evans A. Antioxidants, but not B-group vitamins increase the resistance of low-density lipoprotein to oxidation: a randomized, factorial design, placebo-controlled trial. Atherosclerosis. 1999 Jun;144(2):419-27.

Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR, Hopkins PN. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem. 1994 Apr;40(4):552-61.

Wu LL. Review of risk factors for cardiovascular diseases. Ann Clin Lab Sci. 1999 Apr-Jun;29(2):127-33. Review.

Wuillemin WA, Solenthaler M. [Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis] Vasa. 1999 Aug;28(3):151-5. German.

Xu H, Chen Z, Tang J. [Genetic polymorphisms of homocysteine metabolism related enzymes in patients with coronary heart disease] Zhonghua Yi Xue Za Zhi. 1999 Jun;79(6):414-6. Chinese.

Yoo JH, Chung CS, Kang SS. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke. 1998 Dec;29(12):2478-83.

Yoo JH, Park JE, Hong KP, Lee SH, Kim DK, Lee WR, Park SC. Moderate hyperhomocyst(e)inemia is associated with the presence of coronary artery disease and the severity of coronary atherosclerosis in Koreans. Thromb Res. 1999 Apr 1;94(1):45-52.

Zampolli A, de Caterina R. [Hyperhomocysteinemia and vascular disease] G Ital Cardiol. 1996 Jul;26(7):821-37. Italian.

Zeitlin A, Frishman WH, Chang CJ. The association of vitamin b 12 and folate blood levels with mortality and cardiovascular morbidity incidence in the old old: the Bronx aging study. Am J Ther. 1997 Jul-Aug;4(7-8):275-81.

Zhang Q, Wang X, Guo JX. [Helicobacterium pylori infection and coronary heart disease] Sheng Li Ke Xue Jin Zhan. 1999 Jan;30(1):41-4. Chinese.

Zhu YQ, Zhang CH, Chen GH. [Homocysteine: an independent risk factor for atherosclerosis] Sheng Li Ke Xue Jin Zhan. 1997 Oct;28(4):334-6. Chinese.

Zidek W. Homocysteine - a new arteriosclerotic risk factor in end-stage renal failure. Nephron. 1997;75(3):249-50.